Identification of the Microbiota Metabolite, Indole, as a Novel Immune Modulator for Antigen-Presenting Cells in the Gut by Hunt, Carrie Lynn
  
 
 
IDENTIFICATION OF THE MICROBIOTA METABOLITE, INDOLE, AS A NOVEL 
IMMUNE MODULATOR FOR ANTIGEN-PRESENTING CELLS IN THE GUT 
 
 
A Dissertation 
by 
CARRIE LYNN HUNT  
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
Chair of Committee,  Robert C. Alaniz 
Committee Members, Noah Cohen 
 Robin Fuchs-Young 
 Jon Skare 
Head of Department, Warren Zimmer 
 
August 2016 
 
Major Subject: Medical Sciences 
 
 
Copyright 2016 Carrie Lynn Hunt
ii 
 
 
 
ABSTRACT 
 
Mammals are colonized by trillions of symbiotic microbes, termed the microbiota. This 
collection of predominantly bacteria greatly outnumbers the host’s own cells in number, 
genomic content, and biochemical potential. Extensive research has revealed the 
necessity of the microbiota for developing a fully functional intestinal and systemic 
immune system. While definitive crosstalk between host microbiota and immune system 
exists, the discrete compounds responsible for altering immune cell function remain to 
be fully characterized. Antigen-presenting cells (APCs) are fundamental regulators of 
immunity and integrate signals from their local environment to direct immune responses. 
Primary roles of APCs include antigen presentation to naïve T cells, tissue integrity 
maintenance, and cytokine secretion to instruct activity of other immune cells. APCs 
residing at mucosal sites have a unique role in maintaining homeostasis by promoting 
peripheral tolerance to harmless commensal microorganisms. The dysregulation of this 
phenomenon promotes chronic inflammation in the intestinal tract, which predisposes 
the host to numerous cancers and metabolic disorders. Identifying and manipulating the 
specific microbiota components that drive tolerance in the gastrointestinal tract is a 
primary goal of current immunological research. 
 
Indole is a microbiota-derived metabolite produced by numerous bacterial species and 
present at high concentrations in the intestines. Previous work from our lab and others 
has demonstrated a protective role of indole in the GI tract. In this study, we show that 
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indole is able to suppress pro-inflammatory responses and promote mucosal phenotype 
and function in APCs. Remarkably, indole-conditioned dendritic cells (DCs) imprinted 
naïve T cells with gut-homing markers and preferentially induced regulatory T cells. Our 
overall findings reveal that indole conditions DCs towards a mucosal phenotype in a 
manner mechanistically distinct from the canonical GI signal, retinoic acid. In addition, 
indole-conditioned DCs are capable of promoting a regulatory phenotype in naïve T 
cells. These observations reveal a novel mechanism by which an endogenous microbiota 
metabolite conditions APCs for optimal function in mucosal tissues, thus providing 
evidence for a single metabolite promoting properties associated with peripheral 
tolerance. This revelation paves the way for future work in manipulating the microbiota 
for therapeutic potential in autoimmune and inflammatory disorders of the GI tract. 
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NOMENCLATURE 
 
APC Antigen-presenting cell 
BMDC Bone marrow-derived dendritic cell 
BMDM Bone marrow-derived macrophage 
TLR Toll-like receptor 
LPS Lipopolysaccharide 
CpG CpG oligodeoxynucleotide 
HK-STM Heat-killed Salmonella typhimurium 
RA Retinoic acid 
Treg Regulatory CD4+ T helper cell 
Th1 CD4+ T helper type 1 
Th2 CD4+ T helper type 2 
Th17 CD4+ T helper type 17 
AhR Aryl hydrocarbon receptor 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
The anatomy and organization of the gut-associated lymphoid tissue (GALT) 
Of all the anatomical locations of the human body, the immune tissues associated with 
the gastrointestinal (GI) tract are perhaps charged with the most difficult task: to 
maintain a hyporesponsive tolerance towards the trillions of commensal microorganisms 
and environmental antigens to which it is constantly exposed, while remaining poised to 
initiate appropriate inflammatory responses against invading pathogenic organisms. 
Most human pathogens enter the body via mucosal surfaces, including the intestines (1), 
thus a strong and accurate immune response is crucial to prevent dissemination of 
infection. Meanwhile, inappropriate activation of immunity against harmless bacteria 
results in tissue damage and chronic inflammation, which are detrimental to the host and 
increase predisposition towards a multitude of inflammatory disorders. The delicate 
balance between immune tolerance and activation is achieved in a variety of ways that 
make the intestines a truly unique immunological site. 
 
The organization of intestinal immune components is uniquely suited to support these 
opposing functions. A single layer of simple columnar epithelial cells lines the intestinal 
tract, separating the immense bacterial load in the intestinal lumen from the underlying 
host tissues. Tight junctions and adherens junctions assist in regulating epithelial 
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permeability and seal the paracellular space between cells (2). Intestinal goblet cells 
secrete mucins, forming a two-layered mucus barrier that largely prevents molecules and 
bacteria from contacting the epithelial layer (3). 
 
Despite these mechanisms, immune cells contact the intestinal lumen environment in a 
number of ways. Intraepithelial lymphocytes, predominantly CD8+ T cells expressing αβ 
or γδ T cell receptors, are embedded within the epithelial layer (4). In addition, dendritic 
cells and macrophages have a unique ability to extend their dendrites between epithelial 
cells, enabling antigenic sampling across the epithelium. The expression of tight junction 
proteins by these specialized APCs allows the epithelial integrity to be maintained (5). A 
principal component of peripheral tolerance in the GI tract is the regulatory T cell 
(Treg), which actively suppresses effector T cells and prevents tissue damage from 
excessive inflammatory responses (6).
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Figure 1. Anatomy and organization of gut-associated lymphoid tissue (GALT). 
 
Organized lymphoid tissues are present throughout the gut. Peyer’s patches are lymph 
node-like structures located along the small intestine, whereas isolated lymphoid 
follicles are distributed in both the small and large intestines. Specialized “M” cells 
facilitate transcytosis of antigens across the epithelial surface. Numerous immune cells, 
including B cells, T cells, dendritic cells, and macrophages reside within these tissues. 
Immune cell trafficking to mesenteric lymph nodes via the lymphatic system is mediated 
by expression of the chemokine receptor, CCR7. Activated immune cells can be 
redirected back to the intestinal microenvironment by expression of chemokine receptor, 
CCR9. 
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Much of the gut-associated lymphoid tissue (GALT) is organized into distinct tissues: 
the mesenteric lymph nodes (MLNs), Peyer’s patches (PPs) and isolated lymphoid 
follicles (ILFs; Figure 1). Lymph nodes are critical initiation sites for adaptive immune 
responses against pathogens and are where dendritic cells present antigen to naïve T 
cells. It was discovered over a century ago that oral administration of a protein results in 
“immunologic unresponsiveness” upon systemic challenge using that same antigen (7). 
This phenomenon known as oral tolerance is essential for preventing aberrant immune 
responses against innocuous dietary antigens. An elegant study by Worbs et al. 
demonstrated that the MLNs are the exclusive site of oral tolerance induction and that 
this process relies upon antigen-loaded DCs migrating from the intestines to the MLNs 
(8). 
 
 
Peyer’s patches are lymph node-like structures located along the small intestine that are 
important for facilitating immune responses in the gut. Peyer’s patches have a distinct 
dome-like appearance, containing numerous B cell lymphoid follicles (approximately 10 
in mice and several hundred in humans) surrounded by smaller T cell areas and dendritic 
cells in the subepithelial dome (9). Distinct from lymph nodes, Peyer’s patches lack an 
outer capsule and have persistent germinal centers, likely indicative of continual immune 
stimulation by luminal antigens (10). A follicle-associated epithelium separates these 
immune cells from the gut lumen and contains microfold, or M cells, specialized in 
transporting luminal vesicle-bound antigens across the epithelial surface and released in 
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the extracellular space below (transcytosis) for phagocytosis by dendritic cells. An 
important role of Peyer’s patches is serving as the primary source of IgA-secreting 
plasmablasts that home to the small intestine (11). IgA is the dominant class of antibody 
in the mucosal system, secreted into the intestinal lumen at a rate of approximately 3 
grams per day in humans (12). This secretory IgA binds to the mucus layer, which lines 
the epithelial surface, serving a crucial protective role by preventing adherence of 
bacteria as well as neutralizing toxins. 
 
Isolated lymphoid follicles (ILFs) are similar in structure to Peyer’s patches and 
distributed in both the large and small intestines. These lymphoid aggregates also rely 
upon M cells for transcytosis of luminal antigen to the immune cells below, however 
ILFs are mainly composed of B cells (13). Both Peyer’s patches and ILFs are connected 
via the lymphatic system to the draining MLNs, thus allowing for migration and 
associated interaction of immune cells amongst these gut-associated lymphoid tissues. 
 
 
Nearly 80% of an individual’s immune cells belong to the mucosal-associated immune 
system, with the majority of these cells residing in the GI tract (14). This distribution of 
the immune system in extremely close proximity to trillions of bacterial antigens is not 
coincidental, and emerging evidence continues to reveal the vital importance of immune 
cell-microbiota crosstalk for optimal host immunity.
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The microbiota is essential for proper immune system development and function 
The trillions of symbiotic microorganisms that colonize a host are termed the microbiota. 
The most prevalent microbes are bacteria, reaching concentrations of 1012 cells per gram 
of luminal content in the colon and outnumbering the host’s own genomic content by a 
factor of 200 (15). These commensal organisms have co-evolved with the host over time, 
having established a symbiotic relationship in order to promote homeostasis and prevent 
elimination by the immune system. Numerous beneficial effects of the microbiota have 
long been recognized, including colonization resistance against pathogens, (16) synthesis 
of vitamin K and most B vitamins (17), and fermentation of fiber to produce 
metabolically active products (18). While current research is drastically expanding our 
appreciation for the role of the microbiota in shaping health and disease by metabolic, 
immune, and additional means (19), the mechanism by which the microbiota regulates 
host immunity largely remains a “black box”. Metabolites produced by the microbiota 
have emerged as a major possible pathway for mediating these effects. 
 
 
Elegant studies utilizing germ-free mice have demonstrated the necessity of the 
microbiota for proper development of a fully functional intestinal and systemic immune 
system, with sterile animals exhibiting intestinal tissue defects, reduced nutritional and 
endocrine function, and high susceptibility to infection (20-22). Above all, both GI and 
systemic immune responses are impaired without the presence of commensal bacteria 
(23). It is evident that special adaptations in the immune system and its regulation, 
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particularly in the gut mucosa, have evolved to allow for a symbiotic co-existence with 
the microbiota. 
 
Conserved pattern recognition receptors (PRRs) on the surface of innate immune cells 
recognize pathogen-associated molecular patterns (PAMPs), initiating immune 
responses upon detection of non-self molecular motifs. Dendritic cells and macrophages 
express all four identified classes of PRRs, including transmembrane-spanning Toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs), as well as cytoplasmic NOD-like 
receptors (NLRs) and retinoic acid-inducible gene (RIG)-I-like receptors (RLRs). A 
crucial distinction by the host immune system must be made to determine whether the 
microorganism is a harmless commensal to be tolerated or a potential pathogen to which 
immunity should be activated. The distinct mechanisms that mediate this differentiation 
remain largely obscure, but substantial evidence points to local signals in the intestinal 
microenvironment mediated by APCs (discussed below). 
 
Dysbiosis in the GI tract linked to inflammatory conditions 
 
The gastrointestinal tract is the predominant site of interaction between the host immune 
system and microbiota. Imbalances in the composition of the microbiota, termed 
dysbiosis, disrupt the mutually beneficial relationship between microbiota and host 
immune system. Dysbiosis typically manifests as a change in microbiota composition 
and reduction in diversity. This disturbance promotes aberrant immune responses and 
chronic inflammation in the intestinal tract, predisposing the host to a wide array of 
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pathologies including colon cancer, inflammatory bowel disease, and metabolic 
disorders (24-26).  
 
Inflammatory bowel disease (IBD), encompassing both ulcerative colitis (UC) and 
Crohn’s Disease (CD), describes a group of related chronic inflammatory disorders of 
the GI tract with a steadily increasing global incidence (27). While genetic predisposing 
factors have been identified, it is well established that environmental factors play a 
substantial role in progression of the disease (28). The current dogma is that IBD is 
mediated by chronic inflammation in the GI tract likely resulting from inappropriate host 
immunity towards microbiota constituents (29). A likely driving factor for this condition 
is dysbiosis resulting from an imbalance of protective versus harmful bacteria (30, 31). 
Indeed, despite high variability amongst individuals, the microbiota composition of IBD 
patients is distinct from the healthy population (30, 32). 
 
An interesting genetic comparison of colon biopsies from UC patients against their 
healthy twins revealed that UC is associated with lower biodiversity, unusual aerobic 
bacteria, and a greater proportion of bacteria of the Proteobacteria and Actinobacteria 
phyla (33), both of which are upregulated in  IBD (26). A current challenge in this field 
is determining whether alterations to the microbiota are a cause of IBD versus a 
secondary phenomenon. For example, adherent-invasive Escherichia coli (AIEC) is well 
correlated with the ileum of Crohn’s disease patients; however, whether outgrowth of 
this pathogen is a mediator of Crohn’s disease or a secondary opportunistic pathogen 
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remains to be determined (34). 
 
Conventional therapeutics for IBD including tumor necrosis factor (TNF) inhibitors, 
corticosteroids, and antibiotics are largely focused on suppressing inflammation in the 
GI tract. These options, in addition to surgical intervention, come with possible severe 
consequences and long-term adverse effects (35). Due to the chronic nature of IBD, 
therapeutics are administered long-term with the goal of maintaining remission and are 
accompanied by side effects including immune suppression, osteoporosis, steroid 
dependence, and an enhanced risk of active tuberculosis (36). Thus, the development of 
novel therapeutics for IBD is in great demand. Recent attention has been given to 
modulating the dysbiosis associated with IBD by means of bacterial therapy with the 
goal of repopulating the dysbiotic gut with protective commensal organisms. While 
probiotic and prebiotic administration have generally not been successful in attenuating 
IBD symptoms (37), the recent advent of fecal microbiota transplantation (FMT) appears 
to offer great promise (38). While well controlled studies are lacking, a systematic 
analysis of available FMT studies revealed that the majority of subjects have 
experienced an overall reduction in IBD symptoms and use of mediation as well as 
remission of disease and resolution of C. difficile infection (39). Despite the therapeutic 
potential suggested by early successes of microbiota transplant for suppressing IBD 
symptoms, numerous caveats prevent this from being a useful, mainstream therapeutic 
strategy. Safety is the ultimate concern when transferring live microorganisms into a 
recipient person. While screening of potential donors includes testing for known fecal 
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pathogens and transmittable diseases, there is a concern that undetected pathogens might 
be unintentionally transferred (38).  
 
FMTs are impractical due to the frequency of administration required to maintain 
benefits, the unstable and potentially biohazardous nature of fecal material, and the 
impractical route of transfer, with available options consisting of nasogastric tube, upper 
tract endoscopy, colonoscopy, or retention enema (40). Given these constraints, the use 
of immune-modulating endogenous metabolites purified from the microbiota would 
represent a potentially valuable therapeutic approach, which circumvents current safety 
and practicality issues associated with FMTs. Thus, identifying and manipulating the 
specific microbiota components that drive tolerance in the GI tract is a primary goal of 
current immunological research. 
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Antigen-presenting cells in the gut maintain a unique, tolerogenic role 
Among the multiple cell types present in the GI tract, antigen-presenting cells (APCs) 
are fundamental regulators of immunity that integrate signals from their local 
environment to direct immune responses in the context of antigen presentation to naïve T 
cells (Figure 2). APCs of the intestinal mononuclear phagocyte system have a unique 
role in maintaining homeostasis by promoting peripheral tolerance, a state of immune 
hyporesponsiveness towards harmless commensal microorganisms and nominal dietary 
components, which protects the host from aberrant inflammation. Indeed, these APCs 
are charged with discriminating harmful from harmless in an environment rich in 
immune-stimulating antigens including lipopolysaccharide, peptidoglycans, CpG- 
containing DNA, lipoproteins, and flagellin. 
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Figure 2. Mechanism of naïve T cell activation by a dendritic cell. 
 
The activation of a naïve T cell by an antigen-loaded dendritic cell (DC) typically 
requires three signals. The first is interaction between the T cell receptor (TCR) and 
major histocompatibility complex (MHC)-peptide complex on the DC. The second 
signal is interaction of DC costimulatory markers (often CD80 or CD86) with CD28 co- 
receptor on the T cell. The third signal comes from the DC and can be soluble or cell 
contact-mediated. This is most commonly cytokine production by the DC, which 
interprets environmental signals and secretes appropriate cytokine signals to instruct the 
lineage fate of the newly activated T cell. 
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The two major classes of professional APCs, dendritic cells (DCs) and macrophages – 
each with specialized subtypes – have distinct yet complementary roles in regulating 
intestinal immunity. Both DCs and macrophages are found throughout the lamina 
propria as well as the Peyers’ Patches, isolated lymphoid follicles, and related mucosa- 
associated lymphoid tissues (41). Activated DCs constitutively migrate from the lamina 
propria to the mesenteric lymph nodes, in a CCR7-dependent manner (42), where they 
present antigen to naïve T cells and secrete factors that polarize T cells toward various 
effector fates (43). These gut-associated lymphoid tissue (GALT) DCs possess unique 
properties including preferential induction of regulatory T cells, antigen sampling across 
the intestinal epithelium, induction of B-cell class switching to IgA, and promotion of 
gut-homing properties on lymphocytes (5, 44-46). This is in stark contrast to peripheral 
DCs in largely sterile tissues that migrate to draining lymph nodes and present the 
offending antigen to naïve T cells upon engagement of their pattern recognition 
receptors (e.g., TLRs). This antigen presentation by peripheral DCs typically primes the 
adaptive immune system to an effector Th1 or Th2 response for robust pathogen 
clearance. Through incompletely understood mechanisms, intestinal DCs constitutively 
produce retinoic acid, which drives mucosal DC-specific functions including Foxp3+ 
Treg induction, imprinting of gut-homing CCR9 on DCs and T cells, and B cell class 
switching to IgA (discussed below) (15).  
 
In contrast to DCs, the primary function of macrophages is centered around local 
clearance of pathogens from the tissue.  Additional functions include alerting other 
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immune cells of inflammatory insults as well as producing cytokines to maintain the 
local homeostatic environment and T cell reactivation (47). T cell-mediated colitis has 
been found to induce massive mesenteric lymph node recruitment of monocytes that 
differentiate to inflammatory macrophages and drive Th1 differentiation both in vitro 
and in vivo (48). An influx of newly differentiated macrophages is similarly observed in 
human IBD (49). While tolerogenic APCs appear crucial for gut homeostasis and most 
evidence points to a local conditioning on DC and macrophage precursors after arrival 
from circulation into the mucosa (50), the gut-specific signals that mediate the 
acquisition of these properties remain incompletely understood. 
 
Known APC-modulating signals are present in the GI tract 
Retinoic acid 
While definitive crosstalk between host microbiota and immune system exists, the 
discrete compounds responsible for regulating immune cell function remain to be fully 
characterized. Relatively few gut-tropic immune modulators have been reported for 
APCs. Retinoic acid (RA), a metabolite produced by the host-mediated catabolism of 
dietary vitamin A, is perhaps the best-characterized signal in the gut. The precursor 
retinol and its chaperone, retinol-binding protein (RBP) are taken up into APCs via 
surface receptor STRA6 (51). Retinol is then reversibly oxidized to retinal by alcohol 
dehydrogenases, and the final irreversible step in retinoic acid production is mediated by 
intracellular retinaldehyde dehydrogenase (52)(Figure 3). Importantly, retinaldehyde 
dehydrogenase expression is tightly regulated at both the cellular and tissue level, 
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keeping retinoic production strictly controlled (53). This mechanism ensures that RA is 
produced by and biologically available to RA-responsive cells, including APCs. 
 
RA is currently the only identified inducer of mucosal homing markers on DCs. The role 
of RA in imprinting gut homing markers on T cells has been elegantly demonstrated by a 
marked reduction in intestinal-dwelling T lymphocytes in vitamin A-deficient mice (53). 
In addition, RA appears to be a critical factor in mucosal DC-mediated generation of 
IgA+ B cells, as this function can be modulated by the antagonism or addition of 
exogenous RA (45). A role for RA in Foxp3+ Treg generation has been well 
demonstrated in the activation of naïve T cells by lamina propria-derived DCs (54, 55). 
Interestingly, it has been demonstrated that activation of primary DCs in the presence of 
RA can induce production of transforming growth factor-β (TGF-β) (56), revealing a 
mechanism by which components of the intestinal environment act in synergy to 
promote additional tolerogenic factors. 
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Figure 3. Metabolism of dietary vitamin A results in retinoic acid production. 
 
Dietary vitamin A is converted to retinol in the small intestine, which is then taken up by 
cells including dendritic cells. Retinol is then converted to retinal by a series of alcohol 
dehydrogenases. The final reaction is catalyzed by aldehyde dehydrogenase 1a2 
(aldh1a2), a tightly regulated enzyme which produces biologically active all-trans 
retinoic acid. 
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TGF-β 
 
The cytokine, transforming growth factor-β (TGF-β) is another well characterized host- 
derived molecule present at high concentrations in the gut, produced by every leukocyte 
lineage including dendritic cells, macrophages, and lymphocytes (57). TGF-β has a 
predominant immunosuppressive role, acting by several mechanisms including 
inhibiting DC maturation and promoting the Treg lineage (55, 58, 59). Exposure to TGF- 
β during BMDC development inhibits subsequent antigen-presenting capacity, 
suggesting a means by which TGF-β dampens T cell activation in the intestinal 
environment (60). Mucosal DCs readily produce TGF-β both in vitro and in vivo (58), 
and TGF-β has been identified as an essential co-factor in MLN-derived DC induction of 
Foxp3+ Tregs (55). 
 
Several other molecules of host-derived origin, including IL-10, vasoactive intestinal 
peptide, and thymic stromal lymphopoetin have been reported to modulate intestinal DC 
maturation and function (61, 62). Additional signals are produced by bacterial 
components of the microbiota and can modulate APCs. Of these microbiota-derived 
signals, Bacteroides fragilis polysaccharide A (PSA) and short-chain fatty acids 
(SCFAs, discussed below) are the most fully characterized and both appear to promote 
tolerogenic properties in immune cells. However, millions of bioactive microbiota 
products remain to be characterized. Thus, the identification of additional microbiota- 
derived factors affecting APC phenotype and function in the gut would provide 
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important information on the functional mechanisms by which the microbiota regulates 
intestinal immunity. 
 
Some microbiota metabolites have been identified as immunomodulators 
 
Short-chain fatty acids (SCFAs) 
 
While a few microbiota products have been reported to influence host physiology and 
immunity (Figure 4), the compounds responsible for microbiota control of host 
immunity are largely unknown. Receiving the most attention are the SCFAs, 
characterized decades ago as bacterial fermentation products of dietary fiber. This class 
of metabolites, typified by its predominant members butyrate, propionate, and acetate, 
are produced by Firmicutes and Bacteroidetes bacterial strains at millimolar levels in the 
human colon (63). Molecular characterization of these SCFAs indicates that they 
function as histone deacetylase (HDAC) inhibitors and ligands for G protein-coupled 
receptors in immune cells (64, 65). The clinical relevance of SCFA therapy in the GI 
tract has been established, with some IBD patients receiving benefit from SCFA- 
containing enemas (66). Indeed most studies have focused on the direct effects of 
SCFAs in the colon, demonstrating a preferential induction of regulatory T cells which is 
mediated by increased Treg gene expression and suppressive capacity in a GPR43- 
dependent manner (67-69). 
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Figure 4. Known host and microbiota mechanistic regulators of intestinal APCs. 
 
Known gut-centric molecules which induce tolerogenic APCs include microbiota- 
derived short-chain fatty acids (SCFA) and Bacteroides fragilis with its outer 
membrane component, polysaccharide A (B. fragilis- PSA). The established, 
predominant host- derived factors which drive tolerogenic DC properties are the 
cytokine transforming growth factor-β (TGF-β) and the dietary vitamin A metabolite, 
retinoic acid (RA). Mucosal DCs express high levels of the enzyme aldehyde 
dehydrogenase 1a2 (aldh1a2) which catalyzes the RA-producing reaction, thus 
producing high concentrations of RA in the microenvironment. This RA acts directly 
upon DCs and CD4+ T cells to affect gene transcription for downstream effects 
including preferential induction of Foxp3+ Tregs, expression of gut-homing CCR9 
receptors, class switching to IgA+ in B cells, and suppressed inflammatory responses to 
TLR stimuli. 
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Immune modulating effects of the SCFA, butyrate, have also been reported in bone 
marrow-derived macrophages including inhibition of HDACs. This inhibitory activity 
led to an increase in histone 3 lysine 9 acetylation (H3K9Ac) at the promotor regions of 
IL6, IL12b, and Nos2, resulting in decreased production of pro-inflammatory IL-6, IL-12 
and nitric oxide (70). These anti-inflammatory responses were also observed in primary 
lamina propria-isolated macrophages; however, butyrate-supplemented drinking water 
was not able to ameliorate DSS-induced colitis (70). While the reason for this failure of 
protection is unknown, it should be noted that the DSS-treated mice were also 
administered daily oral antibiotics to deplete butyrate-producing bacteria, thereby 
drastically altering the microbiota and undoubtedly producing off-target effects. 
 
Polysaccharide A from Bacteroides fragilis 
 
The capsular polysaccharide A (PSA) of the commensal bacteria B. fragilis has gained 
recent attention as an immune-modulating microbiota product. An impressive study 
utilizing the CD4+CD45Rb transfer model of colitis demonstrated that wild-type but not 
a PSA-deficient strain of B. fragilis is able to protect against experimental colitis, 
thereby identifying PSA as the essential immune-modulating component (71). 
Subsequent work by the same group demonstrated that monocolonization of germ-free 
animals with B. fragilis efficiently suppressed inflammation by inducing IL-10- 
producing Foxp3+ Tregs in the gut in a PSA-dependent manner (72). Ultimately, the 
studies revealed the mechanism that requires TLR2 recognition by DCs of PSA 
packaged within outer membrane vesicles (73). Intriguingly, TLR2 expression on T cells 
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is insufficient to mediate this effect (73). This compelling finding demonstrates a 
biological situation in which antigen-presenting cells are required for sensing a microbial 
product and subsequently modulating downstream T cell activation and function. We 
predict that other microbiota metabolites are similarly capable of instructing APCs in 
their interactions with other immune cells. 
 
Indole 
 
Indole is a strictly microbiota-derived metabolite produced from tryptophan by 
numerous Gram-positive and Gram-negative bacterial species that express the 
tryptophan lyase enzyme, such as Escherichia coli (74, 75). Already well established as 
an inter- and intra-species bacterial communication signal (75-78), more recent work has 
suggested that indole may also act as an inter-kingdom signaling molecule (74). Indole is 
freely diffusible and present in human and mouse luminal contents at concentrations 
reaching millimolar levels (79, 80), indicating direct contact with immune cells of the 
GALT. We and others have reported immune modulating properties of this metabolite. 
 
We first identified that indole strengthens epithelial barriers and reduces pro- 
inflammatory signaling in human intestinal epithelial cells (74). In vivo beneficial effects 
of indole have also been reported in germ-free mice, with indole-treated mice 
demonstrating increased resistance to dextran sodium sulfate-induced colitis (81). 
Interestingly, a beneficial effect of indole administration was also observed in specific 
pathogen-free (SPF) mice, demonstrating that indole promotes and strengthens the 
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intestinal epithelial barrier in both germ-free and SPF mice (81).  
 
In agreement with these observations, we have recently demonstrated that indole 
supplementation reduces intestinal injury and inflammation induced by non-steroidal 
anti-inflammatory drugs (NSAIDs; (82)). Based on our work in intestinal epithelial cells 
we predict that indole’s beneficial effects might be due to support of epithelial barrier 
function and dampening of pro-inflammatory signaling; however, future work will aim 
to elucidate the mechanisms by which indole attenuates damage in NSAID enteropathy. 
Overall, there is strong evidence to suggest that indole is a beneficial signal in the GI 
tract that merits further investigation in to cell type specificities and mechanism of 
action. 
 
 
Aryl Hydrocarbon Receptor (AhR) 
 
Our previous identification of indole as a ligand of the immune-modulating aryl 
hydrocarbon receptor (AhR) suggests a potential mechanism of action (83). The AhR is 
a ligand-activated transcription factor that binds exogenous and endogenous polycyclic 
aromatic hydrocarbon ligands, inducing nuclear translocation and binding to the AhR 
nuclear translocator (ARNT), followed by the AhR:ARNT complex binding the dioxin 
response element (DRE) DNA sequence and modifying subsequent gene transcription 
(84). Activation of the AhR mediates various cellular activities including response to 
environmental toxins, proliferation, differentiation, and cytokine secretion (85). 
 
 23 
 
While first identified as a receptor for the industrial toxicant dioxin (84), a meaningful 
role for the AhR in shaping immune responses has been appreciated- particularly in the 
gut. AhR appears to regulate Th17 versus Treg induction and is crucial for the 
maintenance and function of innate lymphoid cells (ILCs) and intraepithelial 
lymphocytes (IELs) in the gut (85-87). The presence of AhR on innate immune cells 
coupled with its ability to recognize environmental signals has led some to consider AhR 
as a potential pattern recognition receptor-like sensor for nutritional or metabolic-driven 
immune responses (88). 
 
The specific function of AhR in APCs is incompletely characterized and appears highly 
ligand dependent (85). A screening study was performed to query a panel of AhR 
ligands (6-formylindolo [3, 2-b] carbazole (FICZ), indole 3-carbinol (I3C), curcumin, 
quercetin, and ligand precursor tryptophan) on their abilities to affect BMDC 
characteristics (88). Interestingly, all included AhR ligands augmented LPS-induced pro- 
inflammatory cytokine production (88), which appears contradictory to the established 
immunosuppressive nature of AhR activity (89). In contrast, a recent article identifies 
immune modulation of DCs by AhR agonist, 4-n-nonylphenol, as the mechanism for 
Treg induction and immune suppression in their immune sensitization model (90). It has 
also been reported that BMDCs derived from AhR-deficient mice are less capable of 
inducing Foxp3+ Tregs, suggesting that AhR signaling in DCs is involved in Treg 
induction (91). These findings suggest that AhR is active in DCs and can affect their 
function, thus an investigation of DC- and macrophage-specific AhR activation by an 
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endogenous intestinal ligand would provide important knowledge in the area of 
microbiota-immunity crosstalk. 
 
Based on our published data and the reports of indole as a homeostasis-promoting factor 
in the gut, the exposure of APCs to high indole concentrations in the intestines and the 
crucial role of APCs in peripheral tolerance, we hypothesize that the endogenous 
microbiota metabolite, indole, is a novel gut mucosa signal that promotes intestinal 
homeostasis by inducing a mucosal phenotype and function in APCs. 
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CHAPTER II 
INDOLE DIRECTLY CONFERS MUCOSAL PROPERTIES UPON 
DENDRITIC CELLS 
Overview 
The factors responsible for conferring mucosal properties upon dendritic cells in the 
GALT remain incompletely characterized. Based on the abundance of indole in the 
lower gastrointestinal tract and the resulting direct proximity of indole to mucosal 
antigen-presenting cells, we hypothesized that indole acts as a signal for DCs that 
induces tolerogenic properties. This study begins by investigating the direct influence of 
indole conditioning on DC phenotype and function. The following findings emerged: 
1. Indole selectively inhibits pro-inflammatory cytokine and signaling pathways
in dendritic cells in an AhR-independent manner. 
2. Indole does not alter antigen-presenting cell properties of dendritic cells.
3. Indole induces homing markers on dendritic cells.
Rationale 
The majority of gut-tropic immune modulators that have been reported are derived from 
the host. Retinoic acid and TGF-β have distinct roles in shaping antigen-presenting cells 
for mucosal function; however, neither of these signals is responsible for imprinting 
dendritic cells with all of the tolerogenic properties observed in the gut. Intestinal 
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inflammation results in a loss of tolerogenic properties of mucosal DCs that cannot be 
rescued by adding endogenous RA to the system (92). This observation implicates 
additional mechanisms responsible for local conditioning of mucosal dendritic cells. 
 
One of the putative signaling molecules is indole. This microbiota-derived metabolite is 
freely diffusible and present in the gut lumen of humans and mice at concentrations 
reaching millimolar levels (79, 80), indicating direct contact with immune cells of the 
lamina propria that sample the luminal contents. Furthermore, we have previously 
demonstrated that indole strengthens epithelial barriers and reduces pro-inflammatory 
signaling in human intestinal epithelial cells (74), suggesting a role for indole in 
maintaining GI tract tolerance. The beneficial effects of indole have also been 
demonstrated in both germ-free and conventional mice where indole-treated mice 
displayed increased resistance to dextran sodium sulfate-induced colitis; however, the 
possible contribution of antigen-presenting cells in this model was not addressed (81). 
Intriguingly, fecal levels of indole are reduced in UC patients (93), suggesting reduced 
indole production by the inflamed microbiota. Collectively these findings lead us to the 
hypothesis that the dysbiosis associated with colitis favors non-indole producing 
bacteria, and the absence of local DC conditioning by indole contributes to the observed 
loss of tolerogenic DC properties. Thus, we set out to determine whether indole might 
promote a tolerogenic phenotype and function in dendritic cells. 
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Results 
 
Indole selectively inhibits pro-inflammatory cytokine and signaling 
pathways in dendritic cells in an AhR-independent manner 
 
Pro-inflammatory cytokines 
 
One important way that DCs shape local immune responses is through the production of 
cytokines. Because we had previously observed that indole dampens the gene expression 
of pro-inflammatory cytokines in intestinal epithelial cells (74), we first addressed 
cytokine production in indole-conditioned dendritic cells. We began our query in the 
murine dendritic cell line, DC2.4. As predicted, cells pre-treated with physiologically 
relevant doses of indole produced less TNF upon stimulation with the bacterial surface 
component and TLR4 ligand, LPS. Production of TNF was reduced by 50% following 
treatment with 1 mM indole (Figure 5). This response is biologically important as LPS 
serves as the prototypical endotoxin, present on the surface of virtually all gram-negative 
bacteria including gut-resident commensal strains. Thus, our results demonstrate the 
ability of indole to tolerize DCs against a relevant, inflammatory bacterial signal. 
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Figure 5. Overnight indole treatment inhibits TNF production in DC2.4 cell line. 
 
Flow cytometric analysis of DC2.4 cells treated with indole for 24 hours and stimulated 
with LPS (1 ug/ml) or HK-STM (2 x 105 CFU) for 4 hours in the presence of Golgiplug 
protein transport inhibitor. Intracellular staining was performed to assess TNF 
production. (A) Representative histograms where shaded gray areas represent 
unstimulated samples. (B) Mean of three independent experiments. * p < 0.05 by 
Student’s t test comparing indole-treated DCs to solvent control (DMF). 
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We then generated bone marrow-derived DCs (BMDCs) as described previously 
(94)(Illustrated in Figure 6). Briefly, bone marrow was harvested from femurs of mice 
and cultured for 7 days in the presence of DC-skewing cytokines, GM-CSF and IL-4. 
Treatment of these cultures with indole for 18 hours followed by TLR stimulation 
resulted in a similar inhibition of TNF production, reaching a magnitude of nearly 2-fold 
inhibition (Figure 7). We also queried the pro-inflammatory cytokines, IL-6 and IL-12 
and found 2-fold or greater inhibition of cytokine production with overnight indole 
treatment (Figure 8). Immune cells communicate largely through the production of 
soluble factors including cytokines, and DCs detect these signals and determine their 
effector functions accordingly. Thus, the inhibition of pro-inflammatory cytokine 
production induced by indole conditioning would suggest that indole dampens DC 
responses to immunogenic signals, providing a potential mechanism by which mucosal 
DCs “ignore” harmless commensal bacteria in the gut.  
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Figure 6. Culture methods used for bone marrow-derived and splenic APCs.  
 
(A) Bone marrow was harvested from femurs of C57BL/6 mice and cultured for 7 days. 
BMDC cultures were supplemented with 20 ng/ml GMCSF and 10 ng/ml IL-4 with 
media replenished on days 2, 4, and 6. In some experiments, indole was added to the 
culture from day 3. BMDM cultures were supplemented with 10 ng/ml MCSF with 
media replenished on day 3. (B) Spleens were harvested from C57BL/6 mice and 
homogenized between 2 frosted microscope slides. Heterogeneous splenocytes were 
plated for 24 hours in the presence or absence of indole prior to TLR stimulation. 
Cultures were stained and splenic DCs and macrophages were identified by lineage 
surface markers using flow cytometry. 
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Figure 7. Overnight indole treatment inhibits TNF production in BMDCs. 
 
Flow cytometric analysis of BMDCs treated with indole for 24 hours and stimulated 
with LPS (1 ug/ml) or HK-STM (107 CFU) for 4 hours in the presence of Golgiplug 
protein transport inhibitor. Intracellular staining was performed to assess TNF 
production. (A) Representative histograms where shaded gray areas represent 
unstimulated samples. (B) Mean of three independent experiments. * p < 0.05 by 
Student’s t test comparing indole-treated DCs to solvent control (DMF). 
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Figure 8. Overnight indole treatment inhibits IL-12 and IL-6 production in 
BMDCs. 
 
Flow cytometric analysis of BMDCs treated with indole for 24 hours and stimulated 
with LPS (1 ug/ml) for 4 hours in the presence of Golgiplug protein transport inhibitor. 
Percentage of IL-12 and IL-6-producing DCs indicated, as determined by intracellular 
staining. Representative plots from one of three independent experiments. 
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Because we predict that DC precursors in the intestines are exposed to high 
concentrations of indole during differentiation and development, we investigated the 
effect of indole during BMDC generation. BMDC exposed to indole from the third day 
of their 7 day culture also exhibited a statistically significant inhibition of pro- 
inflammatory cytokine production upon LPS stimulation (Figure 9: 30% reduction in 
TNF and 40% reduction in IL-12, p < 0.05). To confirm the relevance of our 
observations in primary cells, we investigated indole conditioning in splenic DCs ex 
vivo. Because indole is undetectable by mass spectrometry in peripheral tissues outside 
the gut (Arul Jayaraman, personal communication, March 2016), it is likely that splenic 
DCs are indole-naïve. We treated splenocytes isolated from C57BL6/J mice with indole 
overnight, followed by stimulation with LPS or heat-killed Salmonella typhimurium. 
Production of pro-inflammatory cytokines in CD11c+ DCs was assessed via flow 
cytometry. We found a robust inhibition of 2-fold or greater magnitude in production of 
the cytokines TNF, IL-6, and IL-12 by indole-conditioned ex vivo splenic DCs (Figure 
10). This confirmed our in vitro observations that indole inhibits pro-inflammatory 
cytokine production in DCs. 
  
 34 
 
 
Figure 9. Conditioning with indole during differentiation inhibits TNF and IL-12 
production in BMDCs. 
 
Flow cytometric analysis of BMDCs differentiated in the presence of indole from day 3 
and then stimulated with LPS (1 ug/ml) for 4 hours in the presence of Golgiplug protein 
transport inhibitor. Intracellular staining was performed to assess TNF and IL-12 
production. (A) Representative dot plots with percentage of cytokine-producing DCs 
indicated. (B) Mean of three independent experiments. * p < 0.05 by Student’s t test 
comparing indole-treated DCs to solvent control (DMF). 
  
A
B
 35 
 
 
Figure 10. Indole conditioning inhibits pro-inflammatory cytokine production in 
splenic DCs ex vivo. 
 
Flow cytometric analysis of cytokine production by indole-conditioned splenic DCs. 
Splenocytes were cultured for 24 hours with indole, then stimulated with LPS (5 ug/ml) 
or HK-STM (4 x 107 CFU) for 6 hours in the presence of Golgiplug protein transport 
inhibitor. Cultures were then stained for CD11c and intracellular TNF, IL-6, and IL-12. 
Analysis was confined to CD11c+ DCs and maximal cytokine production was 
normalized to solvent control (DMF). Mean of three independent experiments. * p < 
0.05 by Student’s t test comparing indole-treated DCs to solvent control (DMF). 
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NF-kB 
 
We have previously demonstrated a profound inhibition of TNF-induced NF-kB 
signaling in indole-treated intestinal epithelial cells (74). The ubiquitous transcription 
factor NF-kB is a predominant upstream effector mediating numerous inflammatory 
signaling pathways (95), thus we predicted that indole likely affects this signaling 
pathway. Using a DC2.4 cell line transduced with a dual NF-kB reporter plasmid and a 
GLuc reporter, we assayed NF-kB activity subsequent to overnight treatment with 
indole. Many ligands can activate NF-kB including growth factors, cytokines, and 
certain viral and bacterial products. To maintain consistency with our cytokine studies, 
we utilized the bacterial surface molecule LPS to induce NF-kB activity. Indeed, NF-kB 
signaling was inhibited in indole-conditioned cells by approximately one-third (Figure 
11). This level of suppression was greater than that achieved with the positive control, 
TGF-β, and similar to concurrent treatment with both indole and TGF-β. The nuclear 
factor NF-kB pathway lies upstream and mediates transcription of many pro- 
inflammatory genes, including cytokines. Thus, the observed inhibitory effects of indole 
on pro-inflammatory cytokine production might be mediated at the level of NF-kB 
signaling. 
 
To further investigate indole’s effects on NF-kB signaling, we used flow cytometry to 
analyze the phosphorylation of p65 (RelA), a prominent subunit of the NF-kB 
transcription complex important for inflammatory responses (96). Here, we did not 
observe an effect of indole on total p65 phosphorylation or signal intensity in indole- 
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 conditioned BMDCs stimulated with LPS (Figure 12). While this finding would seem 
contradictory, we have identified an alternative possibility. Our collaborator has 
identified that indole inhibits nuclear translocation of the NF-kB transcriptional complex 
in lymphatic endothelial cells (Sanjukta Chakraborty and Mariappan Muthuchamy, 
personal communication, August 2015). If this is also true in DCs, it would explain the 
inhibition of NF-kB activity despite unaffected p65 phosphorylation. Future studies will 
address this question by utilizing fluorescence microscopy to visualize intracellular 
localization of NF-kB constituents. 
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Figure 11. Indole inhibits NF-kB activity in DC2.4 cell line. 
 
DC2.4-NFkB-GLuc cells were treated with indole +/- TGF-β for 24 hours followed by 
LPS stimulation (10 ug/ml) for 8 or 24 hours. Supernatants were collected and assayed 
for GLuc concentration in terms of relative luminescence units (RLU). * p < 0.05 by 
Student’s t test comparing treated samples to untreated, LPS-stimulated sample. 
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Figure 12. Indole does not alter phosphorylation of NF-kB subunit p65 in DCs. 
 
Flow cytometric analysis of DC2.4 cells treated with indole or DMF control overnight, 
followed by LPS stimulation (10 ug/ml) for the indicated periods of time. Cells were 
stained for the phosphorylated form of the p65 NF-kB subunit and assessed by flow 
cytometry. (A) Percentage of DCs staining positive for p65 phosphorylation and (B) 
mean fluorescence intensities (MFI) of phospho-p65-positive population. One 
representative experiment of three shown. 
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Stat3 
 
Based on our accumulating evidence that indole exerts a suppressive effect on 
inflammatory signaling in DCs, we decided to investigate the potential effect of indole 
on host-derived pro-inflammatory signals via the Signal Transducer and Activator of 
Transcription 3 (Stat3) pathway. To date, seven Stat proteins have been identified, 
having dual roles as signaling proteins in the cytoplasm as well as nuclear transcription 
factors. The Stat family activates a diverse set of genes including those involved with 
growth, survival, and inflammatory processes. The biological importance of Stat3 is 
evidenced by the observation that it is the only Stat whose deficiency results in 
embryonic lethality (97). Persistent activation of Stats occurs frequently when an 
upstream receptor-associated Janus kinase (JAK) becomes overactive due to genetic or 
epigenetic factors (98). It is common for Stat3 to be overexpressed in a variety of human 
cancers (99), and a role for Stat3 hyperactivity in driving DCs towards a cancerous 
phenotype has been established (100). In addition, Stat3 is a necessary transcription 
factor for pro-inflammatory Th17 differentiation. We have observed that indole inhibits 
the Th17 lineage (Steinmeyer et al, in preparation), thus a reasonable hypothesis would 
be that suppression of Stat3 signaling by indole is a mechanism by which Th17 
differentiation is suppressed. 
 
We conditioned BMDCs with indole from day 3 and then induced Stat3 signaling by 
stimulation with IL-6 (Figure 13). While Stat3 has both a tyrosine (Y705) and serine 
(S727) activation site, tyrosine phosphorylation is mediated by Janus kinases and 
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required for Stat3 nuclear localization and subsequent DNA binding (101), thus we 
queried this phosphorylation site for our study. In the absence of an external stimulus, 
phosphorylation of Stat3 was nearly undetectable across all conditions. Stat3 signaling 
was induced by the addition of IL-6, and substantial Stat3 phosphorylation (~18%) was 
observed in control DCs within 5 minutes of stimulation, lasting at least 60 minutes post- 
stimulation (peak of ~30% phosphorylated Stat3). The physiological concentration of 1 
mM indole strongly inhibited Stat3 phosphorylation, with indole-treated DCs reaching 
peak phosphorylation of 8% at 15 minutes post-stimulation. Inhibition of Stat3 was 
observed not only in the percentage of DCs bearing phosphorylated Stat3 but also in the 
magnitude of phosphorylation on a per cell basis. The MFI values were similar between 
indole-treated DCs and controls in the absence of stimulation, but a 2-fold or greater 
suppression was observed in indole-DCs throughout the 60 minute timecourse under IL- 
6 stimulation. This finding is in agreement with our observation that indole inhibits the 
Th17 lineage and suggests that indole may inhibit Stat3 signaling across multiple 
immune cell types. 
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Flow cytometric analysis of BMDCs conditioned with indole from day 3 of culture and 
subsequently stimulated with IL-6 (10 ng/ml) for the given times. Cells were stained for 
phospho-Stat3 and analyzed by flow cytometry. (A) Representative MFIs from one 
experiment of three. (B) Mean percentage of phospho-Stat3-positive DCs from four 
independent experiments. * p < 0.05 by Student’s t test comparing indole-treated DCs to 
solvent control (DMF) at indicated timepoints. 
  
Figure 13. Indole inhibits IL-6-induced pStat3 signaling in BMDCs. 
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An important consideration is that we exclusively used IL-6 for Stat3 activation, 
however many other ligands can induce Stat3 including IL-10, epidermal growth factor, 
oncogenes, and interferons (102). An interesting subsequent study would be to assess 
indole’s effects on Stat3 activation when stimulated by a panel of different factors. 
Based on our hypothesis that indole is a promotor of intestinal tolerance, one intriguing 
possibility would be that indole might be capable of discriminating between pro- 
inflammatory (ie, IL-6) and anti-inflammatory (ie, IL-10)-mediated Stat3 activation. 
Further work would be necessary to test this hypothesis. 
 
Akt 
Another central mediator of cellular signaling is the serine/threonine kinase, Akt (also 
referred to as protein kinase B), which regulates cellular processes including 
metabolism, growth, proliferation, and survival. The Akt pathway is activated by 
numerous receptor tyrosine kinases, cytokine receptors, G-protein-coupled receptors, 
and other molecules which activate the lipid kinase PI3K and result in production of 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). This second messenger acts as a 
docking site at the plasma membrane for Akt where phosphorylation and activation 
occurs. Akt is located upstream of NF-kB and can induce NF-kB signaling via 
phosphorylation of IKKα and Tpl2 (103). We chose to interrogate the effect of indole on 
Akt phosphorylation to determine whether indole’s inhibition of NF-kB might be a 
secondary effect due to modulation of an upstream target. Our investigation revealed that 
treatment with 1 mM indole inhibited LPS-induced Akt phosphorylation in DCs (Figure 
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14). This difference was observed at 30 minutes post-LPS stimulation, where phospho- 
Akt was reduced by over 50% with indole pre-treatment. No difference was observed 
between indole-DCs and controls in the absence of external stimulation, which indicates 
that basal Akt signaling is unaffected by indole. Instead, an inflammatory insult appears 
necessary for indole to dampen Akt phosphorylation. This is important as Akt is 
ubiquitously expressed in DCs and mediates many essential cellular processes, so a 
complete ablation of Akt signaling would be detrimental. Whether downstream 
inhibition of NF-kB is a direct result of indole’s effects on Akt or mediated through a 
distinct pathway remains to be determined. Either way, a robust inhibitory effect of 
indole on multiple pro-inflammatory signaling pathways in DCs has been revealed. 
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Flow cytometric analysis of BMDCs conditioned with indole from day 3 of culture and 
subsequently stimulated with LPS (5 ug/ml) for the given times. Cells were stained for 
phospho-Akt and analyzed by flow cytometry. (A) Representative plots with numbers 
indicating the percentage of pAkt-positive DCs. (B) Mean percentage of phospho-Akt- 
positive DCs from three independent experiments. * p < 0.05 by Student’s t test 
comparing indole-treated DCs to solvent control (DMF) at indicated timepoints. 
  
Figure 14. Indole inhibits pAkt signaling in BMDCs. 
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Anti-inflammatory cytokines 
Based on the close proximity of mucosal DCs to indole in the lower GI tract, we 
predicted that indole may affect specific mucosal DC properties. A well-known regulator 
of immune function abundantly present in the GI tract is TGF-β. This cytokine possesses 
potent anti-inflammatory properties, evidenced by TGF-β-null mice undergoing severe 
inflammation, autoimmunity, and premature death within 2 weeks of birth (104). When 
added to our system, a marked additive effect upon concurrent indole and TGF-β 
treatment was observed in DCs (Figure 15). This finding is striking as it demonstrates 
synergistic effect of two highly-abundant intestinal metabolites, one host-derived and 
one microbiota-derived. 
 
To determine whether this was a specific downregulation of pro-inflammatory cytokines, 
we also examined production of the canonical DC-produced anti-inflammatory 
cytokines, IL-10 and TGF-β. Neither IL-10 nor TGF-β production were affected by 
indole conditioning (Figure 16). Overall these results indicate that indole selectively 
suppresses pro-inflammatory cytokines and signaling in DCs, resulting in a net anti- 
inflammatory effect. 
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Figure 15. Indole synergizes with TGF-β to inhibit TNF production in DCs. 
 
Flow cytometric analysis of DC2.4 cells treated with indole or DMF control for 24 hours 
in the presence or absence of TGF-β (10 ng/ml). DCs were then stimulated with LPS (1 
ug/ml) for 4 hours in the presence of Golgiplug protein transport inhibitor and stained 
for intracellular TNF. Shaded gray areas represent unstimulated samples. Representative 
histograms from one of three independent experiments. 
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Figure 16. Indole does not affect IL-10 or TGF-β production in DCs. 
BMDCs were cultured from day 3 with indole (1 mM) or DMF solvent control. On day 
7, DCs were washed, counted, and plated with LPS (1 ug/ml) for 24 hours. Supernatants 
were collected and analyzed for cytokines (A) IL-10 and (B) TGF-β using commercially 
available ELISA kits. No significant differences were observed between indole and 
DMF-treated DCs in four replicate experiments. (p < 0.05 by Student’s t test) 
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Aryl hydrocarbon receptor (AhR) 
 
Thus far, we have revealed novel biology involving the direct effect of indole on DC 
signaling and cytokine production. Our previous identification of indole as an AhR 
ligand (83) led us to the prediction that the observed effects of indole on DCs might be 
mediated through this pathway. In support of this hypothesis, others have reported that 
activation of the AhR pathway by treatment with the canonical AhR ligand TCDD 
lessened pro-inflammatory signs of colitis in a murine DSS model (105). 
 
To evaluate the possible role of AhR in mediating the anti-inflammatory effects of 
indole on DCs, we acquired AhR-deficient mice and analyzed splenic and bone marrow- 
derived DCs. We first treated splenocytes from AhR-deficient and WT mice overnight 
with indole, followed by stimulation with heat-killed S. typhimurium. Consistent with 
earlier reports, we observed an overall increase in TNF production (~ 40%) by TLR- 
stimulated APCs from AhR-deficient mice (106). Nonetheless, a 2-fold inhibition of 
TNF production was observed in indole-treated DCs derived from both WT and AhR-/- 
mice, indicating that the effect was independent of AhR (Figure 17). Similarly, we 
observed nearly equivalent inhibition of phospho-signaling in indole-DCs generated 
from WT or AhR-/- bone marrow in both our Stat3 (Figure 18) and Akt (Figure 19) 
experiments. Collectively, these experiments establish that indole’s inhibition of pro- 
inflammatory signaling in DCs is entirely independent of AhR. 
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Figure 17. The indole-mediated inhibition of TNF production in DCs is AhR- 
independent. 
 
Splenocytes from WT or AhrKO mice were treated with indole or DMF overnight, 
followed by stimulation for 6 hours with HK-STM (4 x 107 CFU) in the presence of 
Golgiplug protein transport inhibitor. Cells were surface stained for CD11c to 
distinguish DCs followed by intracellular staining for TNF production. Flow cytometric 
analysis was confined to CD11c+ cells. * p < 0.05 by Student’s t test comparing indole-
treated DCs to solvent control (DMF). 
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Figure 18. The indole-mediated inhibition of pStat3 signaling in DCs is AhR- 
independent. 
 
Flow cytometric analysis of BMDCs from WT or AhrKO mice cultured in the presence 
of indole or DMF from day 3. DCs were stimulated with IL-6 (10 ng/ml) for the given 
times and stained for phospho-Stat3, which was detected by flow cytometry. Stat3 
signaling was reported as (A) percent of phosphorylated cells and (B) MFI of the Stat3 
positive population. The specific Stat3 inhibitor, cucurbitacin I, was included as a 
negative control. Representative data from one of four independent experiments. 
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Figure 19. The indole-mediated inhibition of pAkt signaling in DCs is AhR- 
independent. 
 
Flow cytometric analysis of BMDCs from WT or AhrKO mice cultured in the presence 
of indole (1 mM) from day 3. DCs were stimulated with LPS (5 ug/ml) for the given 
times and stained for phospho-Akt, which was detected by flow cytometry. Percentage 
of pAkt-positive DCs indicated. Representative data from one of three independent 
experiments. 
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Indole does not alter antigen-presenting cell properties of dendritic cells 
 
To ensure that our observations were not due to indole-induced alteration of the inherent 
functional capacity of DCs, we performed a series of assays looking at the general 
functions of DCs. We first treated DCs with indole and assessed their viability by 
measuring lactate dehydrogenase release as well as propidium iodide uptake. Results 
from both assays indicated a low level of cellular death which did not differ from solvent 
controls, confirming that indole did not induce cytotoxicity in DCs (Figure 20). The 
ability of antigen-presenting cells to respond to bacterial LPS is dependent upon the 
expression of TLR4 on their surface. We compared TLR4 expression level in DC2.4 and 
BMDC treated for 18 hours with indole as well as BMDC cultured with indole from day 
3 and found that indole does not alter surface TLR4 expression on DCs (Figure 21). In 
the periphery, DCs exist in an immature state with a high phagocytic capacity. Upon 
encountering and engulfing antigen, DCs upregulate their expression of maturation 
markers including MHC-II and the co-stimulatory molecule, CD86. This stimulation 
triggers the migration of DCs to local lymphoid organs and prepares them for 
presentation of peptide fragments to naïve T cells. We treated BMDC with indole from 
day 0, 3, or 6 in culture prior to LPS stimulation. Flow cytometric analysis of MHC-II 
and CD86 expression revealed that the presence of indole did not alter DC maturation 
compared to solvent controls (Figure 22). 
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Figure 20. Indole does not alter DC viability. 
 
DC2.4 cells were cultured with or without indole (1 mM) for the indicated timepoints 
and cell viability was assessed. (A) Percent cytotoxicity was calculated as a measure of 
the cytosolic enzyme lactate dehydrogenase. (B) Propidium Iodide (PI) labeling was 
performed at the indicated timepoints and percent viability was determined by flow 
cytometry. Representative data from one of three independent experiments. 
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Figure 21. Indole does not alter TLR4 expression in DCs. 
 
Flow cytometric analysis of surface TLR4 expression following treatment with indole (1 
mM) for 24 hours (DC2.4 and BMDC) or during development from day 3 (BMDC D3). 
Blue line represents indole-treated DCs, black line represents DMF solvent control, and 
gray shaded areas are unstained controls. Representative data from one of three 
independent experiments. 
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Figure 22. Indole does not alter DC maturation. 
A                                                                             B 
 
 
 
 
 
 
Flow cytometric analysis of BMDCs treated with indole (1 mM) from day 0, 3, or 6 of 
differentiation, then cultured for 24 hours in the presence or absence of LPS (1 ug/ml) 
and surface stained for CD86 and MHC-II (I-Ab). (A) Representative histograms where 
blue line represents indole-treated DCs, black line represents DMF controls, and shaded 
gray areas are unstained controls. Mean fluorescent intensity (MFI) indicated on 
representative FACS plots. (B) Mean percentage of DCs expressing surface CD86 
(upper panel) or MHC-II (lower panel). No significant differences observed between 
indole- treated DCs and DMF controls in four replicate experiments. (p < 0.05 by 
Student’s t test) 
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Production of reactive oxygen species (ROS) by DCs is an established component of 
DC-T cell interactions (107, 108). We investigated the secretion of reactive oxygen 
species (ROS) and nitric oxide (NO) in DC2.4 and BMDC. Our results confirmed that 
these properties of DCs were also intact regardless of indole treatment (Figures 23 and 
24). The phagocytic ability of DCs was examined by incubating DCs with FITC-labeled 
OVA particles, then analyzing via flow cytometry. Indole did not alter particle uptake by 
DCs (Figure 25). Together, these results indicate that indole does not interfere with 
general APC functions of DCs but is instead selectively dampening inflammation 
through some alternative mechanism. 
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Figure 23. Indole does not alter reactive oxygen species production in DCs. 
 
Flow cytometric analysis of DC2.4 (upper panel) and BMDCs (lower panel) cultured in 
the presence of indole (1 mM) or DMF for 18 hours, then labeled with CellRox and 
stimulated with LPS. The presence of ROS oxidizes CellRox reagent to a fluorescent 
state, which was subsequently analyzed via flow cytometry. Representative data from 
one of three independent experiments. 
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Figure 24. Indole does not alter nitric oxide production in DCs. 
 
DC2.4 cells (upper panel) or BMDCs (lower panel) were cultured with indole or DMF 
for 24 hours in the presence of either LPS, LPS and IFNγ, or no stimulation. Nitric oxide 
(NO) content in the supernatant was measured by the Griess reaction. No significant 
differences in NO production observed between indole-treated DCs and DMF controls in 
three replicate experiments. (p < 0.05 by Student’s t test) 
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Figure 25. Indole does not alter antigen uptake in DCs. 
 
Flow cytometric analysis of antigen uptake by DC2.4 (upper panel) and BMDCs (lower 
panel). Subsequent to 24 hour indole conditioning, DCs were incubated with Ovalbumin 
(OVA)-FITC conjugate at 4°C or 37°C for 1 or 4 hours. BMDCs were surface stained 
for CD11c and all DCs were fixed with paraformaldehyde. Uptake of FITC-OVA 
antigen was measured by flow cytometry. Percentage and MFI of FITC-OVA-positive 
DCs indicated on histograms. Representative data from one of three independent 
experiments. 
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Indole induces homing markers on dendritic cells 
Dendritic cell subsets bear numerous surface antigens that regulate their migration and 
localization. Because indole is produced in the gut and appears to induce anti- 
inflammatory properties in DCs, we hypothesized that indole might affect migration and 
retention in mucosal tissues. Thus, we looked at expression of the gut homing marker, 
chemokine receptor CCR9. Remarkably, we observed that indole strongly induced 
CCR9 on BMDC, indicating that indole imprints DCs with gut-homing specificity 
(Figure 26). Retinoic acid was included as a positive control. RA is present in murine 
plasma at approximately 1 uM (109) and is predicted to exist at higher concentrations in 
tissue microenvironments in vivo (110), thus we chose to use 1 uM as a conservative 
estimate of relevant physiological concentration. Indole’s effect was even more profound 
than that of retinoic acid, a known inducer of mucosal homing markers on T cells (53). 
Surface expression of CCR9 on indole-conditioned DCs reached 34%, compared to 22% 
on RA-conditioned DCs and 10% on solvent controls. Upregulation of this gut homing 
marker would suggest that in addition to suppressing pro-inflammatory signaling, indole 
imparts gut homing signals upon DCs to preferentially maintain them within the 
intestinal environment. 
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Figure 26. Indole induces CCR9 and B220 on DCs. 
 
BMDCs were cultured in the presence of indole (1 mM), retinoic acid (1 uM), or DMF 
solvent control from day 3. On day 7, DCs were surface stained for expression of CCR9 
and B220 and analyzed by flow cytometry. (A) Data reported as percentage of surface 
marker-expressing DCs and (B) corresponding MFI values. Mean of three independent 
experiments. * indicates p < 0.05 for one-way ANOVA followed by Dunnett’s post-test. 
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One possible explanation for these observations would be that indole promotes retinoic 
acid availability to the DCs, thus inducing gut homing markers indirectly by providing 
substrate for a previously identified mechanism. To investigate this possibility, we 
analyzed aldehyde dehydrogenase (ALDH) activity via flow cytometry using the 
fluorescent ALDH substrate, Aldefluor. Surprisingly, we found that indole does not 
affect ALDH activity in DCs (Figure 27). We confirmed this observation by assessing 
gene expression of aldehyde dehydrogenase family 1 subfamily A2, a rate-limiting 
enzyme for retinal metabolism in DCs (Figure 27). Thus, indole utilizes a novel 
mechanism for inducing gut-homing markers on DCs, apparently independent of retinoic 
acid availability. 
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Figure 27. Indole does not induce aldehyde dehydrogenase activity in DCs. 
 
(A) BMDCs cultured from day 3 with indole (1 mM), retinoic acid (1 uM), or DMF 
control were assayed for aldehyde dehydrogenase (ALDH) activity using the Aldefluor 
commercial kit. The ALDH inhibitor, DEAB reagent, was included to control for 
background fluorescence. Aldefluor fluorescence as a measure of ALDH activity was 
analyzed by flow cytometry. Data reported as percentage of Aldefluor positive DCs (left 
panel) and corresponding MFI values (right panel). Individual dots represent data from 
five independent experiments. (B) Gene expression of aldh1a2 was assayed by real-time 
qPCR in day 7 BMDCs cultured with indole from day 3. Gene expression was 
normalized to 18s ribosomal RNA. Mean of three independent experiments. * p < 0.05 
by Student’s t test. 
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We also observed an indole-induced upregulation of the B220 (CD45R) antigen (Figure 
26), which is widely used to distinguish the plasmacytoid DC lineage and is believed to 
contribute to gut homing. However, more recently B220 has been reported to distinguish 
a DC subset more closely developmentally related to conventional rather than 
plasmacytoid DCs and a precursor to resident CD8+ and CD8- conventional DCs (111). 
This upregulation denotes a differential conditioning effect between RA and indole, as 
RA does not induce B220 on BMDCs (110). Further inquiry would be necessary to 
determine the physiological importance of indole’s upregulation of B220 on BMDCs. 
 
Encountering maturation-inducing stimuli induces an upregulation of the chemokine 
receptor CCR7 in DCs. This shift promotes DC migration from peripheral tissues to the 
lymph nodes to present captured antigen. CCR7 expression facilitates this migration by 
rendering DCs sensitive to the chemoattractants, CCL19 and CCL21, which direct DCs 
to T cell areas of lymphoid tissues (112). We observed that indole conditioning during 
BMDC development resulted in a pronounced increase in expression of CCR7 in day 7 
freshly harvested DCs, approximately 5-fold greater than RA or solvent controls (Figure 
28). Exposure to LPS is a DC-activating signal known to upregulate CCR7 expression in 
order to prime DCs for lymph node entry. Consistent with the literature, exposure to LPS 
for 24 hours further induced CCR7 expression in our BMDC cultures overall. Here, 
indole-conditioned DCs once again expressed a higher level of CCR7 expression 
compared to controls by over 3-fold in magnitude (Figure 28). This enhancement in 
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CCR7 expression would suggest a superior capacity for lymph node homing and entry 
by indole-conditioned DCs. 
 
We utilized an in vitro chemotaxis assay to test for functional relevance of the observed 
CCR7 and CCR9 upregulation by indole. Consistent with the literature, DCs grown in 
the presence of RA exhibited enhanced migration to the CCR9 ligand, CCL25, while 
migration towards CCR7 ligands were unaffected (53, 113). However, indole- 
conditioned BMDCs did not demonstrate enhanced migration towards either ligand 
(Figure 29). While unexpected, it is important to consider the caveat that this assay was 
performed in vitro and does not accurately mimic the true physiological environment. To 
further this line of study, we propose the use of an in vivo transfer of indole-conditioned 
and control DCs to identify their true capacity of migration to physiological ligands at 
their target sites. 
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Figure 28. Indole upregulates CCR7 expression in DCs. 
 
Flow cytometric analysis of BMDCs cultured from day 3 in the presence of indole (1 
mM), RA (1 uM), or DMF control and either surface stained for CCR7 expression 
directly or treated with LPS (1 ug/ml) for 24 hours prior to CCR7 staining. (A) 
Representative histograms with percentage of CCR7-positive DCs and corresponding 
MFIs indicated. (B) Mean of three independent experiments. * indicates p < 0.05 for 
one-way ANOVA followed by Dunnett’s post-test. 
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Figure 29. Indole does not enhance DC migratory capacity to CCR7 and CCR9 
ligands in vitro. 
 
Day 7 BMDCs conditioned from day 3 with indole (1 mM), RA (1 uM), or DMF control 
were placed in the upper chamber of a transwell cell culture plate with 8.0 uM 
polycarbonate membrane. Chemokines CCL19 and CCL21 (CCR7 ligands) or CCL25 
(CCR9 ligand) were added to the bottom chamber at a concentration of 1 ug/ml each. 
Cells were incubated for 3 hours at 37°C, then migrated DCs in the bottom chamber 
were recovered and counted. Migration is reported as a proportion of the initial 
population in the upper chamber. Transwells without chemokines were included as a 
negative control for migration. Mean of three independent experiments. * p < 0.05 by 
Student’s t test. 
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To test whether indole non-specifically upregulates all chemokine receptors, we also 
analyzed CCR2, the cell surface receptor for Monocyte Chemoattractant Proteins 
(MCPs). CCR2 recruits immune cells to sites of inflammation and tissue injury (114) 
and would be considered an irrelevant marker as our studies are focused on DCs of the 
intestinal tract. We found no appreciable difference in CCR2 expression between indole- 
conditioned and control DCs (Figure 30). This finding supports the prevailing paradigm 
that indole selectively modifies expression of certain surface antigens on DCs, including 
those that have a beneficial role in the gut. 
 
The membrane-spanning integrin, CD103, is present on numerous immune cell types 
including intraepithelial T cells, some peripheral Tregs, and lamina propria cells. Most 
DCs in the small intestinal lamina propria express CD103 (115), as well as DC subsets 
in the Peyers Patches (116), colonic lamina propria and mesenteric lymph nodes (46). 
Dendritic cells bearing CD103 possess specific mucosal properties: carrying antigen 
from the intestines to the mesenteric lymph nodes (117, 118), inducing gut homing 
markers on T cells (116), and potently inducing regulatory T cells (54). In addition, DC 
expression of CD103 has been reported to be necessary for suppressing T cell-mediated 
colitis in an adoptive transfer model (119). 
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Figure 30. Indole does not affect CCR2 expression on DCs. 
 
Day 7 BMDCs conditioned from day 3 with indole (1 mM), RA (1 uM), or DMF control 
were surface stained for expression of CCR2 and analyzed by flow cytometry. No 
significant differences in CCR2 expression observed between indole-treated DCs and 
DMF controls in three replicate experiments. (p < 0.05 by Student’s t test) 
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Figure 31. Indole does not induce CD103 expression in BMDCs in vitro. 
 
BMDCs conditioned from day 3 with indole (1 mM), RA (1 uM), or DMF control were 
surface stained for expression of CD103 and analyzed by flow cytometry. No induction 
of CD103 expression observed in BMDCs under any treatment across three replicate 
experiments. (p < 0.05 by Student’s t test) Mesenteric lymph node cells included as 
positive control for staining. ND, not detected. 
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The mechanism by which CD103 expression is regulated remains unresolved, but one 
possibility is that expression is driven by contact with components of the intestinal 
microenvironment. Thus, we sought to test whether indole induces CD103 expression on 
dendritic cells. Our results revealed that indole conditioning during development of bone 
marrow-derived DCs did not induce CD103 expression (Figure 31), which suggests that 
indole does not confer all mucosal properties upon DCs. However, it is important to note 
that while retinoic acid is an established inducer of CD103 expression on DCs in vivo, it 
is insufficient for inducing CD103 on BMDCs in vitro (110). This suggests that other 
factors in addition to retinoic acid are necessary for DC CD103 induction. Thus, the 
possibility that indole plays a partial role in mediating CD103 DC expression in vivo 
cannot be discounted. 
 
Discussion 
In this chapter, we have revealed a novel and previously unappreciated modulation of 
DC phenotype and function by a single endogenous microbiota metabolite. To our 
knowledge, the effect of indole on DCs has not been interrogated. Previous 
investigations by our group and others have focused on the immune modulatory effects 
of indole on intestinal epithelial cells and naïve T cells (74, 81). In this study, we have 
expanded our efforts to include dendritic cells, which play a critical role in mediating 
peripheral tolerance in the lower GI tract. As predicted, conditioning with indole appears 
to suppress subsequent pro-inflammatory responses by DCs in response to TLR stimuli. 
The inhibition of NF-kB signaling is consistent with our earlier observation in intestinal 
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epithelial cells (74). We also observed indole-mediated inhibition of the additional pro- 
inflammatory pathways, Stat3 and Akt. While beyond the scope of this study, it is 
interesting to note that all three of these pathways are associated with overexpression or 
persistent activation in multiple human cancers. Further investigation into indole and its 
potential development for an immunosuppressive anti-cancer agent may be worthwhile. 
The suppression of multiple ubiquitous pathways would suggest that the cellular target 
of indole is upstream of common effectors, possibly at the level of TLR signaling. 
However we have demonstrated that indole does not alter surface TLR4 expression, 
which leaves the receptor mechanism of indole’s effects on DCs to be elucidated. 
 
Our finding that effects of indole on DCs are AhR-independent was unexpected as 
evidence from the interaction of AhR with host-derived endogenous tryptophan 
metabolites supports a regulatory role for AhR ligands in DCs. The presence of AhR is 
required for induction of the host-derived enzyme, indoleamine-2,3-dioxygenase (IDO). 
This enzyme catalyzes the degradation of tryptophan into kynurenine along with other 
metabolites. Kynurenine is an endogenous AhR ligand and its addition to DC-T cell co- 
cultures results in enhanced Treg induction and corresponding inhibition of Th17 
differentiation (91). Early exposure of immature DCs to environmental signals 
determines whether they will express IDO, and IDO- DCs are characterized by 
immunogenicity whereas IDO+ DCs appear regulatory in nature (120). These IDO+ DCs 
produce high levels of TGF-β and IL-10 (120), both of which are immunosuppressive 
and associated with Treg induction. Thus, AhR-dependent tryptophan metabolism by the 
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host-enzyme IDO produces kynurenine, an AhR ligand which imparts tolerogenic 
properties upon DCs. These studies using host-derived tryptophan metabolites contrasted 
with our current work with a microbiota-derived metabolite suggest that AhR activities 
might be differentially regulated based on origin of the AhR ligand. 
 
In addition, we propose that the ligation and downstream effects of AhR signaling are 
highly context dependent. Previously we found indole to exhibit antagonist AhR activity 
in CaCo-2 intestinal cells (83), while both agonistic and antagonistic AhR effects have 
been previously reported for indole in yeast and a liver cancer cell line, respectively 
(121, 122). Indeed, both agonistic and antagonistic activities have been identified in 
numerous AhR ligands as well as tissue/cell-specific activities (123). Indole is a small 
(MW = 117.15), hydrophobic molecule shown to be freely diffusible across membranes 
(76). Therefore, indole might bind to either extracellular or intracellular receptors. 
Future investigation into the binding site of indole will be tremendously advantageous in 
further characterizing the biological activities of this metabolite. 
 
Due to the largely suppressive nature of the effects of indole on DCs, it is possible that 
our observations are a result of a general dampening of DC function. Importantly, we 
provide evidence here that indole does not modify any general antigen-presenting cell 
functions in DCs. This is important, as inhibition of DC maturation is a mechanism by 
which factors including IL-10 and TGF-β promote tolerogenic DCs (124). In fact, the 
long held paradigm has been that immature and semi-mature DCs drive T cell anergy 
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and Treg formation, whereas fully matured DCs promote immunogenic responses (61). 
Evidence in recent years has demonstrated unequivocally that fully mature, antigen- 
loaded DCs are capable of possessing tolerogenic properties (61); thus, factors 
independent of maturation status are involved in mediating DC tolerance versus 
immunogenicity. Our findings suggest that indole may be one of these previously 
unidentified factors. 
 
An intriguing finding in our study is the observation that indole upregulates homing 
markers on DCs. Indole-conditioned DCs exhibited enhanced CCR7 expression (Figure 
28), which indicates a superior capacity to traffic to and enter the lymph nodes. As 
CCR7 ligands are secreted in T cell areas of lymph nodes (125), we speculate that 
indole-mediated CCR7 upregulation may augment interactions between DCs and naïve 
T cells in situ. 
 
Similarly, indole conditioning appears to upregulate CCR9 on DCs. Cells expressing 
CCR9 selectively migrate to its specific ligand, CCL25, produced in the small intestine. 
Our identification of indole as a suppressor of inflammatory signaling coupled with 
CCR9 induction support our hypothesis that indole promotes tolerogenic characteristics 
in DCs. Outside of the mucosa, tissues are largely sterile and thus DCs are highly 
immunogenic in order to prime a rapid and effective adaptive immune response against 
invading pathogens. Therefore, it would be logical to confine indole-instructed, 
tolerogenic DCs to the GI tract where anti-inflammatory properties are essential. This 
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finding is particularly novel as the current notion is that RA is indispensable for CCR9 
upregulation in DCs. Here, we have identified that a single microbiota metabolite is 
similarly capable of this action. We have shown that the molecular mechanism of action 
is not enhanced metabolism of RA, hence indole modulates DC properties through a 
novel mechanism that remains to be defined. 
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CHAPTER III 
INDOLE-CONDITIONED DENDRITIC CELLS MODULATE NAÏVE T CELL 
ACTIVATION 
Overview 
 
In chapter two we have revealed indole as a novel microbiota signal that imparts direct 
modulation of dendritic cell phenotype (homing markers) and function (cytokine 
production). Dendritic cells are classified as professional antigen presenting cells, with 
their predominant function being naïve T cell activation. Thus, our next focus was 
investigating whether indole conditioning of DCs could modify their interactions with 
naïve T cells and ultimately modify T cell lineage skew. To this end, we studied DC-T 
cell interactions and reported the following observations: 
 
1. Indole-conditioned DCs preferentially induce Tregs under both monoclonal 
and polyclonal stimulation. This effect appears to be AhR-independent and cell 
contact-dependent. 
2. Indole-conditioned DCs induce gut homing CCR9 on naïve T cells. 
3. Indole-conditioned DCs inhibit Th1, Th2, and Th17 lineage differentiation. 
 
Rationale 
The predominant general function of DCs is their activation of naïve T cells (Figure 32). 
In addition to providing the MHC-peptide complex and co-stimulatory factors, DCs also 
secrete cytokines that aid in the lineage determination of the naïve T cell. This phenotype 
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of the newly activated T cell determines its functional capacity, thus DCs are largely 
responsible for immune activation versus tolerance. Intestinal DCs play a crucial role in 
mediating homeostasis in the gut, allowing for the activation of inflammatory responses 
against pathogens while promoting local immunological tolerance to prevent aberrant 
inflammation. A major functional feature of gut mucosal DCs is their propensity to induce 
anti-inflammatory regulatory T-cells rather than pro-inflammatory effector T-cells (55). 
Based on our previous observations in intestinal epithelial cells (74) and our current 
observations in DCs, indole appears to suppress pro-inflammatory signals. Thus, we 
predict that indole will condition DCs to mimic primary mucosal DCs by promoting 
regulatory T cells. While few host-derived factors such as retinoic acid and TGF-β have 
been identified as signals that induce Tregs (55), potential remaining signals responsible 
for conferring mucosal properties to DCs remain to be characterized. Determining whether 
the microbiota-derived metabolite, indole, can modify DC interactions with T cells in a 
manner consistent with gut DCs would be a novel finding with enormous therapeutic 
potential. 
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Figure 32. Dendritic cells interact with naïve T cells to determine effector lineage. 
 
Antigen-loaded dendritic cells (DC) activate naïve T cells by presenting antigenic peptide 
and interacting with co-stimulatory molecules, along with a third signal mediated by 
soluble factors or cell contact. This signal from the DC, such as cytokine production, 
determines the effector lineage and resulting downstream function of the newly activated 
T cell. Mucosal DCs preferentially induce regulatory T cells (Treg) by soluble or cell 
contact-mediated mechanisms. 
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Results 
Indole-conditioned DCs preferentially induce Tregs under both monoclonal and 
polyclonal stimulation 
To test our hypothesis that indole-conditioned DCs would preferentially induce Tregs, 
we employed a co-culture system using FACS-sorted wild-type naïve CD4+CD25- T 
cells. These naïve T cells were activated by antibodies against CD3 and CD28 in the 
presence of indole-conditioned BMDCs and cultured for 72 hours (see Figure 33 for 
diagram of experimental design). Under this model of polyclonal stimulation, we 
observed a 2-fold increase in Treg induction in indole-DC cultures compared to controls 
(Figure 34). While this finding supports our hypothesis, we chose to pursue the same 
question in a more physiologically relevant model; i.e. under monoclonal T cell 
stimulation. To this end, we performed similar experiments using an in vitro antigen- 
presentation assay with naïve CD4+CD25- T cells from OT-II transgenic mice that 
express a T cell receptor specific for the peptide sequence 323-339 of chicken ovalbumin 
(OVA) protein in the context of MHC Class II molecules (Figure 35). Purified naïve 
CD4+ T cells were co-cultured with OVA323-339 peptide-pulsed BMDCs that were 
conditioned with indole or retinoic acid from day 3 of development. BMDC preparations 
were washed extensively to remove any residual conditioning agents. Consistent with 
our previous finding, indole-conditioned BMDCs preferentially induced Foxp3+ Tregs, 
an effect dependent upon exogenous TGF-β being added to the cultures (Figure 36). 
Significant Treg induction by indole-DCs above solvent controls was observed when 
TGF-β was added at 10 and 30 ng/ml, achieving 3.5-fold greater Treg induction under 
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these conditions. Significance was not reached when exogenous TGF-β was absent or 
added at a low concentration (2 ng/ml), which leads us to the conclusion that TGF-β is a 
necessary co-factor for preferential Treg induction by indole-conditioned DCs. 
 
In order to confirm that the differences observed were due to newly activated T cells, we 
labeled the naïve T cells with cell proliferation dye prior to co-culturing and tracked its 
dilution. Similar proliferation was observed across all co-culture conditions with 
approximately 60% of the initial T cell population undergoing proliferation (Figure 37), 
thus indicating a similar capacity of antigen presentation by DCs in all groups. This 
result verifies our conclusion that indole-conditioned DCs enhance Treg induction ex 
vivo. 
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Figure 33. Co-culture system for naïve CD4+CD25- T cell and indole-treated 
BMDCs (polyclonal stimulation). 
 
Naïve CD4+CD25- T cells from pooled spleen and lymph nodes of C57BL/6 wild-type 
mice were FACS-sorted to high purity. BMDCs were treated with indole, RA, or DMF 
from day 3. On day 7, DCs were washed extensively prior to co-culture with the naïve 
FACS-sorted T cells for 72 hours in a 96-well round-bottom tissue culture plate in the 
presence of soluble anti-CD3 (5ug/ml). Subsequently, cells were stained for flow 
cytometric analysis. 
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Figure 34. Indole-conditioned DCs preferentially induce Foxp3+ Tregs (polyclonal 
stimulation). 
 
Naïve wild-type CD4+CD25- T cells were sorted and co-cultured with indole- or DMF- 
conditioned BMDCs. Cells were cultured together for 72 hours in the presence of 
soluble α-CD3 (5ug/ml) as well as TGF-β (2 ng/ml) with or without IL-2 (100 U/ml). 
Subsequently, cells were stained for the transcription factor Foxp3 and analyzed by flow 
cytometry. Shaded gray histograms represent unstained controls. Representative data 
from one of four experiments. 
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Figure 35. Co-culture system for naïve CD4+CD25- T cell and indole-treated 
BMDCs (monoclonal stimulation). 
 
Naïve CD4+CD25- T cells of spleen and lymph nodes from OT-II mice were isolated 
via column purification. T cells were labeled with Cell Proliferation Dye then co- 
cultured with OVA peptide-loaded BMDCs at a ratio of 2:1 for 72 hours in a 96-well 
round-bottom tissue culture plate. BMDCs were previously treated with indole or RA 
from day 3. On day 7, DCs were washed and loaded with OVA323-339 peptide (10ug/ml). 
BMDCs were then washed and plated with naïve CD4+ T cells. Following 3 days of 
culture, surface and intracellular staining was performed for flow cytometric analysis. 
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Figure 36. Indole-conditioned DCs preferentially induce Foxp3+ Tregs (monoclonal 
stimulation). 
 
Naïve CD4+CD25- T cells from OT-II TCR transgenic mice were isolated and labeled 
with cell proliferation dye. Naïve T cells were then co-cultured with OVA323-339 
peptide- loaded BMDCs for 72 hours in the presence of TGF-β as indicated. BMDCs 
were previously treated with indole, RA, or DMF from day 3. Following 3 days of co-
culture, surface and intracellular staining was performed for flow cytometric analysis. 
(A) Representative plots with numbers indicating the percentage of Foxp3-positive DCs. 
T cells alone included as negative control. (B) Mean percentage of Foxp3-positive DCs 
from four independent experiments. * indicates p < 0.05 for one-way ANOVA followed 
by Dunnett’s post-test. 
A 
B
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Figure 37. Indole-conditioned DCs induce similar T cell proliferation to control 
DCs. 
 
Naïve CD4+CD25- T cells were labeled with Cell Proliferation Dye prior to DC co- 
culturing experiments. After 3 days, dilution of dye was assessed by flow cytometry to 
determine extent of proliferation. Percentage of actively dividing cells indicated in red. 
Co-culture with DCs lacking OVA peptide (DCs no peptide) included as negative 
control of T cell activation. Representative data from one of three independent 
experiments. 
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Induction of Tregs by indole-DCs is not mediated by soluble factors 
In order to gain insight into the mechanism of indole-mediated Treg skew, we queried 
whether these effects were mediated via soluble factors. Naïve CD4+ T cells were 
polyclonally activated by anti-CD3 in the presence of supernatant from indole-treated 
BMDC cultures. These BMDC supernatants were generated by growing indole-treated 
BMDCs for seven days, then washing and culturing for an additional 24 hours to 
generate indole-free supernatant. Retinoic acid-treated BMDC supernatants were 
included as a positive control and induced Tregs at approximately 2-fold the magnitude 
of solvent control DCs. No significant induction of Tregs was observed with indole-DC 
supernatants beyond solvent controls, suggesting that soluble factors are not responsible 
for indole-DC Treg skew (Figure 38). 
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Figure 38. Conditioned media from indole-treated DCs does not induce Treg 
differentiation. 
 
Naïve CD4+CD25- T cells were FACS-sorted and plated in 96-well, α-CD3 and α- 
CD28-coated tissue culture plates in a volume of 100 ul cell culture media. An equal 
volume of spent DC supernatant from Indole, RA, or DMF-conditioned BMDC cultures 
was added. T cells with DC supernatant were cultured for 72 hours in the presence or 
absence of exogenous TGF-β. Subsequently, cells were stained for the transcription 
factor Foxp3 and analyzed by flow cytometry. Mean of three independent experiments. 
* indicates p < 0.05 for one-way ANOVA followed by Dunnett’s post-test. 
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To validate this observation, we employed an additional culturing method. Here, we 
utilized transwell tissue culture plates to perform co-cultures with a physical barrier 
between the two cell types. Naïve CD4+ T cells were isolated and placed in the bottom 
chamber of the transwell plate, activated by plate-bound anti-CD3. Indole- or RA-treated 
BMDCs were washed and placed in the upper chamber. In this manner, the T cells and 
DCs share common media and secreted factors in the absence of physical contact. Once 
again, indole-conditioned DCs did not enhance Treg skew despite the addition of 
exogenous TGF-β, while positive control RA-DCs enhanced Treg induction 3-fold over 
solvent controls (Figure 39). Our results confirm the supposition that RA-exposed DCs 
preferentially induce Tregs via soluble factors. In addition, we conclude that the 
increased induction of Tregs by indole-DCs does not appear driven by soluble factors 
but is instead likely mediated by a cell contact-dependent mechanism. 
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Figure 39. Indole-conditioned DCs do not induce Tregs when physically separated 
from naïve T cells. 
 
Naïve CD4+CD25- T cells were FACS-sorted and placed in the bottom of a 24-well 
Transwell cell culture plate with 0.4 uM polycarbonate membranes that had been coated 
with α-CD3 (5 ug/ml) and α-CD28 (2 ug/ml). TGF-β was added at the indicated 
concentrations. The insert was placed in the well and indole-, RA-, or DMF-conditioned 
BMDCs were added to the top chamber such that culture media was shared, but the cell 
types were kept physically separate. The T cell to DC ratio was 2:1, as in other co- 
culture experiments. After 3 days, T cells were stained for Foxp3 and analyzed by flow 
cytometry. Mean of three independent experiments. * indicates p < 0.05 for one-way 
ANOVA followed by Dunnett’s post-test. 
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Indole-conditioned BMDCs induce Tregs in the spleen in vivo 
To address the functionality of indole DC-induced Tregs, we employed an in vivo T cell 
activation system (see Figure 40 for schematic representation). The pan T cell surface 
antigen, Thy1, has congenic alleles, Thy1.1 and Thy1.2, which can be used to 
differentiate donor and recipient T cells. We purified naïve CD4+CD25- T cells from 
OT-II (Thy1.2) mice, then transferred them to recipient Thy1.1 mice. We subsequently 
transferred indole-treated, OVA323-339 peptide-loaded BMDCs (Thy1.2) to the same 
recipient Thy1.1 mice. After five days, we sacrificed the recipient mice to assess 
activation of the transferred naïve T cells, which could only be activated by the 
transferred, peptide-loaded DCs and are identifiable by the Thy1.2 T cell surface 
antigen. We examined cellular populations from the spleen, mesenteric lymph nodes, 
and pooled distal lymph nodes (axial and inguinal), limiting our analysis to CD4+ T cells 
bearing the Thy1.2 allele (donor-derived). Importantly, our DCs transferred without 
OVA peptide loading (negative control) induced virtually undetectable T cell activation. 
This confirms the specificity of our model, ensuring that T cell activation in Thy1.2 T 
cells was solely due to interaction with our experimental BMDCs. 
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Figure 40. Model of in vivo T cell activation by indole-conditioned BMDCs. 
 
Naïve CD4+CD25- T cells from spleens and lymph nodes of OT-II mice were isolated 
by column purification. Two million T cells were transferred via i.v. injection (retro- 
orbital route) into recipient B6-Thy1.1 mice. Day 7 BMDCs cultured with indole, RA, or 
DMF from day 3 were washed and loaded with OVA peptide as described above. Two 
million BMDCs were transferred i.p. into the same B6-Thy1.1 recipient mice 5 hours 
subsequent to T cell transfer. After 5 days, tissues were harvested for cellularity analysis 
as well as ex vivo stimulation for cytokine production. 
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All three tissues demonstrated a substantially lower amount of T cell activation in mice 
receiving indole-DCs, more than 2-fold less expansion than controls (Figure 41). In fact, 
T cell expansion induced by indole-DCs was similar to the negative control mice which 
received DCs lacking OVA peptide. This result was in contrast to our ex vivo co-culture 
work where the extent of T cell activation was unaffected by indole-DCs, indicating that 
additional physiological factors might modify T cell activation by indole-DCs in vivo. 
 
Strikingly, of the newly activated T cell population, indole-DCs induced two times more 
Tregs in the spleen compared to either RA-DCs or DMF-DCs. In addition to a greater 
proportion of Tregs, these splenic Tregs had a higher mean fluorescence intensity for the 
Foxp3 transcription factor, indicative of greater Treg stability and suppressive function 
(126). This enhancement of Treg induction supports our hypothesis that indole- 
conditioned DCs promote tolerance in vivo. 
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Naïve CD4+CD25- T cells from OT-II (Thy1.2) mice and OVA323-339-loaded BMDCs 
conditioned with indole, RA, or DMF were transferred to B6-Thy1.1 mice. After 7 days, 
tissues were harvested and stained for flow cytometric analysis. Data includes (A) total 
expansion of Thy1.2+CD4+ T cells, (B) Percentage of Foxp3+CD4+ T cells of expanded 
T cells, and (C) MFI of Foxp3+CD4+ T cells of expanded T cells. n = 4 mice/group. 
One representative experiment of two shown. * p < 0.05 by Student’s t test. 
  
Figure 41. Indole-conditioned DCs induce lower T cell activation overall but a 
greater proportion of Tregs in spleen compared to control. 
 95 
 
 
Indole-conditioned DCs induce gut homing CCR9 on naïve T cells 
 
Based on our observation that indole induces gut homing markers on developing DCs, 
we decided to investigate whether indole-conditioned DCs could also confer gut homing 
markers upon naïve CD4+ T cells. We used our antigen-specific T cell activation model 
to address this question, and a titration of RA was included as a positive control to 
induce CCR9. We found that while indole-conditioned BMDCs alone were insufficient 
to induce CCR9 on naïve T cells, the addition of RA to these cultures resulted in 
significant CCR9 induction above solvent controls (Figure 42). Just 10 nM of RA 
enabled indole-DC co-cultures to achieve over 50% of T cells expressing CCR9 which 
was similar to RA-DC positive controls, whereas DMF-DC co-cultures with the same 
concentration of RA added achieved only 10% of CCR9+ T cells. Throughout our 
titration of RA concentrations ranging 10-1000 nM, indole-DCs consistently induced a 
similar level of CCR9 expression on T cells compared to RA-DCs and a greater level 
than was achieved in DMF-DC controls. This data allows us to conclude that RA is an 
essential co-factor for preferential induction of gut-homing CCR9 on naïve T cells by 
indole-conditioned DCs. The functional significance of this upregulation has been 
demonstrated in vivo, with newly activated T cells bearing CCR9 effectively migrating 
to the small intestine (46, 119). 
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Naïve CD4+CD25- T cells from OT-II mice were co-cultured with OVA323-339 peptide- 
loaded BMDCs for 72 hours in the presence of RA as indicated. BMDCs were 
previously treated with indole, RA, or DMF from day 3. Following 3 days of co-culture, 
surface staining was performed for flow cytometric analysis. (A) Representative plots 
indicating percentage of CCR9+ of total CD4+ cells. (B) Mean of three independent 
experiments. * indicates p < 0.05 for one-way ANOVA followed by Dunnett’s post-test. 
Figure 42. Indole-conditioned DCs induce CCR9 on naïve T cells upon 
activation. 
 97 
 
Indole-conditioned DCs inhibit Th1, Th2, and Th17 lineage differentiation 
 
In order to determine whether the indole-conditioned DC induction of Tregs was specific 
to this lineage, we needed to query additional T cell fates. Activated CD4+ T helper cells 
are typically divided into the subsets Th1, Th2, Th17, and Treg, based on their 
expression of transcription factors and pattern of cytokine secretion. We used our 
antigen-specific co-culture system to investigate these remaining traditional T cell 
lineages with the addition of an endpoint PMA/Ionomycin stimulation to induce 
cytokine secretion. We first examined Th17 induction, as concurrent work in this lab has 
suggested that conditioning of naïve T cells directly with indole in the absence of 
antigen-presenting cells inhibits Th17 differentiation (Steinmeyer et al, in preparation). 
 
In agreement with these observations, we found that indole-conditioned DCs also inhibit 
Th17 differentiation, despite the presence of Th17-skewing cytokines added to the 
culture (Figure 43). The presence of indole-DCs maintained Th17 differentiation at a 
rate of less than 0.5% of T cells, compared to 2.5% Th17 in DMF-DC control cultures. 
Importantly, this indicates that indole conditioning of DCs is able to overcome 
physiological skewing factors which drive Th17 induction. Next, we interrogated the 
Th1 and Th2 lineages that largely mediate cell-mediated and humoral immune 
responses, respectively. Once again, we observed a stark inhibition of the development 
of these lineages (Figure 43). These findings indicate that indole conditions DCs to 
preferentially induce regulatory T cells while suppressing the differentiation of other, 
largely pro-inflammatory, helper T cell lineages. 
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Naïve CD4+CD25- T cells from OT-II TCR transgenic mice were isolated by column 
purification. Naïve T cells were then co-cultured with OVA323-339 peptide-loaded 
BMDCs for 72 hours in the presence or absence of lineage-skewing cytokines (described 
in methods). BMDCs were previously treated with indole, RA, or DMF from day 3. For 
the last 5 hours of culture, T cells were restimulated with PMA and ionomycin in the 
presence of Golgiplug, followed by intracellular staining. Cytokine production was 
determined to assess differentiation of (A) Th1, (B) Th2, and (C) Th17 CD4+ T cells. 
Mean of three independent experiments. * indicates p < 0.05 for one-way ANOVA 
followed by Dunnett’s post-test. 
Figure 43. Indole- conditioned DCs inhibit Th1, Th2, and Th17 differentiation. 
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T cell lineage skewing by indole-DCs is AhR-independent 
 
Using a similar co-culture system, others have reported that AhR-deficient BMDCs 
skew naïve T cell differential away from Tregs (91). Because we have observed skewing 
towards Tregs by indole and we have identified indole as an AhR ligand (83), we sought 
to determine whether Treg skew by indole might be mediated via the AhR pathway. We 
performed antigen-specific T cell activation using naïve T cells from OT-II mice co- 
cultured with indole-treated BMDCs derived from wild-type or AhR-/- mice. Consistent 
with the findings from Nguyen and associates, (91), we observed an overall decrease in 
Treg induction (~30%) when naïve T cells were activated with AhR-/- BMDCs. 
However, similar to our results in chapter 2, we found that the Treg skewing induced by 
indole-conditioned BMDCs was entirely independent of AhR (Figure 44). Similarly, the 
inhibition of the Th1 lineage by indole-conditioned BMDCs was apparent in co-cultures 
using DCs derived from both wild-type and AhR-deficient mice, resulting in our 
conclusion that this effect of indole is also AhR-independent (Figure 44). 
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BMDCs were differentiated from WT or AhR-KO mice and conditioned with indole, 
RA, or DMF from day 3. DCs were then loaded with OVA323-339 and co-cultured with 
naïve CD4+CD25- T cells from OT-II transgenic mice for 72 hours. For Th1 cultures, T 
cells were restimulated with PMA and ionomycin in the presence of golgiplug for the 
last 5 hours of culture. Subsequently, all cultures were stained and analyzed by flow 
cytometry for (A) Foxp3 to identify Tregs or (B) IFNγ to identify Th1 cells. 
 
  
Figure 44. T cell skewing mediated by indole-conditioned DCs is AhR-independent. 
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Transfer of indole-conditioned DCs did not protect against DSS-induced colitis 
Based on our findings that indole-conditioned DCs inhibit pro-inflammatory responses 
and preferentially induce Tregs in vivo, we predicted that transferring these DCs prior to 
the induction of DSS-induced colitis would lessen the severity of colitis in recipient 
mice. This concept has been applied previously with the transfer of Polysaccharide A 
(PSA)-treated BMDCs to mice prior to the induction of TNBS colitis (73, 127). Both 
groups reported lower clinical disease scores in mice to which PSA-treated BMDCs 
were adoptively transferred prior to colitis induction, attributed to both innate and 
adaptive mechanisms. We chose to use the dextran sodium sulfate (DSS) model of 
murine colitis based on the robustness and reproducibility of the model as well as its 
similarities to inflammatory bowel disease in humans, particularly ulcerative colitis. 
 
BMDCs were cultured with indole, RA, or DMF from day 3 as described above and 
transferred to wild-type mice on days 0, 6, and 9 of the experiment. Mice received 5% 
DSS in their drinking water from day 7 to day 14 and were euthanized on day 20 for 
subsequent tissue harvest and processing. Bodyweights of individual mice were tracked 
as an indirect measure of clinical disease. As expected, weight loss peaked a few days 
following the removal of DSS upon which mice began to recover and gain weight. 
Throughout the duration of the experiment, no difference in bodyweight was observed 
between mice receiving indole-treated DCs compared with solvent control-treated DCs 
(Figure 45). Similarly, differences were not apparent between these two groups for the 
following T cell parameters in either spleen or mesenteric lymph nodes: CD4+ T cells, 
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CD8+ T cells, Foxp3+ Tregs, Th1 cells, and Th17 cells (Figure 46). Analysis of antigen- 
presenting cells in these tissues also revealed no differences between indole-DC and 
DMF-DC mice for the presence of total MHC-II+ APCs, macrophages, DCs, and 
CD103+ DCs (Figure 46). These results might indicate that under the current 
experimental conditions, a significant shift in immune cell populations in the spleen or 
mesenteric lymph nodes did not occur. An alternative possibility is that any changes in 
immune cellular subsets had been resolved by the time of tissue harvest on day 20. 
 
A hallmark pathological sign of colitis is shortening of the colon, mediated by abscesses 
forming in the intestinal crypts that disrupt the mucosal architecture and are later 
replaced by scar tissue. An intriguing finding in our study was that the average colon 
length of indole-DC-transferred mice was similar to unmanipulated control mice (~6 
cm), while DMF-DC-transferred and no DC-transferred mice exhibited shorter colons 
(~4.5 cm) at endpoint analysis (Figure 47). Shortening of the colon is an established 
indicator of colitis pathology in the murine model of DSS colitis (128). Thus, our 
observation suggests that indole-DCs might have played some role in mediating 
recovery from colitis that was not detected in our experimental readouts. 
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Figure 45. In vivo transfer of indole-conditioned DCs did not affect weight loss in a 
murine DSS colitis model. 
 
BMDCs were cultured with indole, RA, or DMF from day 3. Two million BMDCs were 
transferred via i.p. injection to WT C57BL/6 mice on days 0, 6, and 9 of the experiment. 
Mice received 5% dextran sulfate sodium (DSS) ad libitum in their drinking water from 
day 7 through day 14. Mice were weighed daily to monitor weight loss. Mice were 
euthanized on day 20 for subsequent tissue harvest and processing. n = 4 mice/group. 
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Figure 46. In vivo transfer of indole-conditioned DCs did not affect spleen or MLN 
cellularity in a murine DSS colitis model. 
 
BMDCs were cultured with indole, RA, or DMF from day 3. Two million BMDCs were 
transferred via i.p. injection to WT C57BL/6 mice on days 0, 6, and 9 of the experiment. 
Mice received 5% dextran sulfate sodium (DSS) ad libitum in their drinking water from 
day 7 through day 14. Mice were euthanized on day 20 for subsequent tissue harvest and 
cellularity analysis as well as ex vivo stimulation for cytokine production. 
Unmanipulated mice served as a negative control. n = 4 mice/group. No differences were 
induced by transfer of indole-conditioned DCs (one-way ANOVA followed by 
Dunnett’s post-test). 
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Figure 47. In vivo transfer of indole-conditioned DCs prevented shortening of colon 
in a murine DSS colitis model. 
 
BMDCs were cultured with indole, RA, or DMF from day 3. Two million BMDCs were 
transferred via i.p. injection to WT C57BL/6 mice on days 0, 6, and 9 of the experiment. 
Mice received 5% dextran sulfate sodium (DSS) ad libitum in their drinking water from 
day 7 through day 14. Mice were euthanized on day 20 and colons were immediately 
removed and measured for length (left panel) and weight (right panel). n = 4 mice/group. 
* p < 0.05 by one-way ANOVA followed by Dunnett’s post-test, comparing to 
unmanipulated control colons. 
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Discussion 
In this chapter, we have identified previously unappreciated biology in which 
conditioning of dendritic cells with a single microbiota-derived metabolite is sufficient 
to modulate its T cell activating functions in a tolerance-promoting manner (Figure 48). 
We demonstrated that indole-conditioned DCs preferentially induce Foxp3+ Tregs in a 
TGF-β-dependent manner, further suggesting a synergistic effect of indole and TGF-β as 
observed in chapter two. This effect was validated in multiple models of naïve T cell 
activation- under both polyclonal (anti-CD3) and monoclonal (antigen-specific OT-II) 
stimulation. The monoclonal stimulation conditions are particularly relevant as this 
mimics true physiological interaction between a naïve T cell and antigen-presenting cell. 
Two signals are essential for a naïve CD4+ T cell to become activated by an antigen- 
presenting cell: First is engagement of the T cell receptor (TCR) by MHC-II on the APC, 
and second is co-stimulation, typically ligation of T cell CD28 by CD80 or CD86 on the 
surface of the APC. We have demonstrated in chapter two that indole does not modify 
general DC function, nor expression of the DC surface molecules MHC-II, CD80, or 
CD86. This evidence suggests that conditioning of DCs with indole leaves the TCR- 
APC complex intact and does not account for observed differences in T cell activation. 
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Figure 48. Indole-conditioned DCs preferentially induce Tregs and inhibit Th1, 
Th2, and Th17 lineages. 
 
Antigen-loaded dendritic cells (DC) activate naïve T cells by presenting antigenic 
peptide and interacting with co-stimulatory molecules, along with a third signal 
mediated by soluble factors or cell contact. This signal from the DC, such as cytokine 
production, determines the effector lineage and resulting downstream function of the 
newly activated T cell. Mucosal DCs preferentially induce regulatory T cells (Treg) by 
soluble or cell contact-mediated mechanisms. The current study provides evidence that 
indole-conditioned DCs preferentially induce Tregs in a TGF-β-dependent manner and 
requires cell contact between the DC and naïve T cell. In addition, indole-treated DCs 
inhibited differentiation of Th1, Th2, and Th17 cells. 
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Our group has previously published on our identification of indole as a ligand of the aryl 
hydrocarbon receptor (83), thus we acquired AhR-/- mice to pursue the question of 
whether AhR ligation is the mechanism of action for indole’s effects on immune cells. In 
addition, we have revealed that the presence of indole during anti-CD3-mediated naïve T 
cell activation also preferentially induces Foxp3+ Tregs. However, studies comparing 
naïve T cells derived from wild-type versus AhR-/- mice indicated that this effect was at 
least partially mediated through the aryl hydrocarbon receptor (Steinmeyer et al, in 
preparation). Therefore it was somewhat surprising to observe that in the current study, 
indole-DC conditioning effects on T cells were entirely AhR-independent, despite 
having observed AhR-independent effects of indole directly on DCs in chapter two. 
Based on these seemingly contradictory observations, we must consider that indole 
might interact with different immune cell subsets by distinct mechanisms. As discussed 
in chapter two, both agonistic and antagonistic activities have been identified in 
numerous AhR ligands as well as tissue/cell-specific activities (123). Further work is 
warranted to determine the molecular mechanism responsible for indole’s specific 
effects on DCs. 
 
We demonstrated using multiple methods that the observed preferential Treg skew by 
indole-DCs requires contact between DCs and naïve T cells. This was an unexpected 
finding, given that the known Treg-skewing elements are soluble factors secreted by host 
immune and epithelial cells. The host-derived cytokine, TGF-β, is present at high 
concentrations in the GALT and is produced by gut epithelial cells as well as various 
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immune cell subsets. This cytokine is well appreciated for its crucial role in intestinal 
homeostasis; TGF-β-deficient mice develop lethal gut and systemic inflammation (104) 
and murine models of colitis are alleviated by TGF-β treatment (129, 130). TGF-β is a 
crucial factor for Foxp3+ Treg induction (131, 132). In a co-culture system similar to 
ours using naïve T cells and CD103+ DCs isolated from murine MLNs, the addition of a 
blocking monoclonal antibody against TGF-β completely abrogated Foxp3+ Treg 
induction (55). Interestingly, authors of this work reported that the addition of 
exogenous TGF-β to these co-cultures induced a strong enhancement of Treg conversion 
in cultures with CD103+ DCs but only a minimal induction with CD103- DCs (55). 
 
When we compare these findings with our current study, it is tempting to speculate that 
conventional BMDCs act similarly to CD103- primary DCs while our indole- 
conditioned DCs exhibit characteristics that mimic mucosal CD103+ DCs. This is 
especially intriguing considering that indole did not induce the expression of CD103 on 
BMDCs in vitro; however, it has been suggested that additional physiological factors 
may be required for CD103 induction (110). A transcriptomic approach would be 
beneficial in the future to compare the genetic signatures of indole-conditioned BMDCs 
to bona fide mucosal DCs. 
 
Consistent with the literature, our retinoic acid-conditioned DCs enhanced Foxp3+ Treg 
skew when supplemented with exogenous TGF-β (55). This supports the notion that both 
TGF-β and retinoic acid are essential components for Treg induction. Indeed, the 
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inclusion of synthetic RA inhibitors (LE540 and LE135) blocked the ability of CD103+ 
MLN DCs to skew naïve T cells towards Foxp3+ Tregs (55), emphasizing the necessity 
of RA in this conversion. 
 
In addition to its role as a co-factor in Treg induction, retinoic acid also enhances the 
expression of chemokine receptor CCR9 and the integrin α4β7 on T cells upon 
activation (53). Retinoic acid is a product of the catabolism of dietary vitamin A, formed 
by intracellular oxidative metabolism of retinol (133). The major physiological form, all- 
trans-RA, binds predominantly to members of the nuclear retinoic acid receptor family 
(types α, β, and γ) (134). We found that in vitro conditioning with RA during 
development was sufficient for BMDCs to induce CCR9 on naïve T cells, whereas 
indole-conditioned BMDCs and control BMDCs did not induce CCR9. However, the 
addition of exogenous RA into the indole-DC co-cultures resulted in a pronounced 
induction of CCR9, similar to the level observed in RA-DC cultures. This finding 
suggests that indole conditioning does not confer RA-producing capacity to DCs, which 
is in agreement with our unexpected finding in chapter two that indole inhibits aldh1a2 
expression and does not induce aldehyde dehydrogenase activity. We instead propose 
that indole affects DCs through an alternative mechanism that remains to be identified. 
Based on the findings presented in this chapter, one hypothesis might be that indole 
primes DCs to exhibit heightened sensitivity to the presence of TGF-β and/or retinoic 
acid, thus explaining the observed synergistic effects. We propose that binding assays 
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would be useful to reveal the site of action for indole in DCs in order to help clarify this 
remaining question. 
 
Our in vivo T cell activation experiments affirm our ex vivo findings that indole- 
conditioned DCs are capable of preferentially inducing Foxp3+ Tregs. We observed this 
Treg enhancement in the spleens of recipient mice, both in proportion of Tregs and 
Foxp3+ mean fluorescence intensity. Using our ex vivo co-culture system we identified 
exogenous TGF-β as an essential co-factor to direct indole-mediated Treg skew; 
however our observation of in vivo Treg skew indicates that any required co-factors were 
present and biologically available. 
 
While we had predicted an increase in Tregs in the MLNs as well, indole-DCs did not 
induce Tregs above solvent control-DCs in this tissue. When contemplating this result, it 
is important to consider that our recipient mice were conventionally-raised, specific 
pathogen-free animals and thus colonized by indole-producing bacteria. These mice 
would have already possessed endogenous DCs conditioned by indole in the MLNs, and 
we speculate that this may account for the lack of effects observed in the MLNs when 
transferring indole-DCs. In contrast, we have found indole to be present at trace levels in 
the blood and virtually undetectable in peripheral organs such as the lungs (unpublished 
observations); thus we assume the spleen to be an indole-naïve organ. This would 
indicate that our transfer experiments introduced indole-conditioned DCs to the spleen 
and this first encounter preferentially induced Tregs. 
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An important extension of this work would be to repeat in mice lacking indole and 
indole-producing bacteria. One way to accomplish this would be by using germ-free 
mice; however, the importance of the intestinal microbiota for a fully functional and 
developed immune system has been well established, and thus using germ-free mice 
would introduce additional variables to the system. The ideal approach would be to 
colonize germ-free mice with a known population of non-indole-producing commensal 
bacterial strains. In this manner, mice would possess normal, fully functional immune 
systems and the effects of adding indole to the system could be addressed. An additional 
set of experiments might include colonizing two groups of mice with a known set of 
commensal bacterial strains, where one group receives mutant strains of the same 
bacteria that have the enzyme, tryptophanase, knocked out. Because this enzyme that 
catalyzes the indole-producing reaction has been identified (135), this approach is 
feasible and would allow for the comparison of immune cell phenotype and function in 
the presence or absence of endogenous indole. 
 
An additional consideration for this in vivo T cell activation work is that the study was 
performed under homeostatic conditions. That is, naïve T cells and indole-conditioned 
DCs were transferred to recipient mice in the absence of any infectious or inflammatory 
insult. It is possible that this might explain the perceived lower T cell activation 
observed in mice receiving indole-conditioned DCs. However, a possible explanation 
might be that the indole-conditioned DCs and/or newly activated T cells migrated to a 
tissue not included in the current study. Based on the indole-induced upregulation of the 
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CCR9 gut homing marker, one possibility is that the T cells activated by indole-DCs 
have migrated to the lamina propria. Further studies should be expanded to include 
examination of the lamina propria and additional tissues to address the question of lower 
activation versus T cell migration induced by indole-DCs. Alternatively, while we did 
not observe this effect in our co-cultures, indole might serve as a general suppressor of T 
cell activation in vivo in the absence of inflammatory stimuli. This overall dampening 
would limit the activation of all lineages, including inflammatory effector T cell subsets. 
Investigating additional T cell lineages would be useful; based on our ex vivo work, we 
predict that indole-DCs selectively inhibit Th1, Th2, and Th17 CD4+ T helper cell 
lineages. 
 
Our observations led us to test the ability of indole-conditioned DCs to alleviate colitis 
severity in vivo. We predicted that under inflammatory conditions, indole-conditioned 
DCs would inhibit the development of inflammation through both the dampening of pro- 
inflammatory cytokine production and the preferential induction of regulatory T cells. 
However, under these experimental conditions, we did not observe a protective effect of 
indole-DC transfer. There are a number of potential explanations for the lack of 
protection. One likely possibility is that our dose of DSS, 5% for 7 days, was too high in 
this experimental setting and caused a level of severe damage to the intestinal epithelium 
that could not be overcome by potential effects of indole-DCs. To address this, we 
would optimize DSS conditions to determine ideal dose and duration of DSS. Our DSS 
procedure of a relatively high dose (5%) for 7 days mimics a more acute disease bout, 
 114 
 
whereas multiple cycles of a lower DSS concentration have been shown to resemble 
chronic intestinal inflammation and might be more relevant for our future experimental 
questions. Early characterization of DSS effects in mice revealed that an acute treatment 
results in colonic mucosal inflammation, weight loss, and bloody diarrhea, whereas three 
to five cycles of DSS induced chronic inflammation with severe mononuclear cell 
infiltration and regenerative changes in the epithelium (136). 
 
In this study, we have demonstrated that indole inhibits DC production of IL-6. While 
this cytokine is typically considered to be a pro-inflammatory mediator, it also has an 
important role as a reparative factor in wound healing (137). Thus, one explanation 
might be that under homeostatic conditions, indole promotes an anti-inflammatory, 
tolerogenic environment while in times of tissue injury, the effect of indole is overridden 
by the need for IL-6 and other wound repairing factors. 
 
Other considerations include the details of the DC transfer: ie, number of DCs 
transferred and timing of transfers. We transferred two million BMDCs, which is the 
same number as in the seminal PSA-BMDC transfer paper but considerably higher than 
the 100,000 and 600,000 BMDC doses transferred in the subsequent publication (73, 
127). The duration of DC life in vivo should be considered, as impaired indole-DC 
survival would lessen interaction with T cells. Indeed, the Shen group transferred PSA- 
BMDCs only two hours prior to TNBS colitis induction (73). Rapid DC turnover in vivo 
has been documented, with lifespan differences reported for different DC subsets (138). 
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In vivo half-life studies comparing indole-treated and control DCs would be useful to 
address possible differences in lifespan. 
 
Lastly, we might consider pursuing alternative rodent models of colitis. The protective 
effects of transferring PSA-loaded BMDCs were observed using the TNBS model (73, 
127) in which colitis develops as a delayed-type hypersensitivity response to haptenized 
proteins (139), whereas DSS colitis develops as a direct result of intestinal barrier injury 
(140). A comparative gene expression analysis of common mouse models of colitis 
suggests that the CD45RB transfer model, which involves transferring a T cell 
population devoid of regulatory cells into an immunodeficient host (141), best resembles 
human inflammatory bowel disease (142). The incorporation of multiple colitis models 
into future studies may be useful to screen for potential benefits of indole-DCs in models 
with varying pathologies, potentially shedding light on the molecular mechanism of 
action for indole. 
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CHAPTER IV 
PRO-INFLAMMATORY SIGNALING IS DOWN-REGULATED IN INDOLE- 
CONDITIONED MACROPHAGES 
Overview 
In addition to dendritic cells, macrophages are the other prominent mononuclear 
phagocyte residing within the intestinal environment. While the primary role of DCs is 
activation of naïve T cells, macrophage functions are centered around clearance of 
bacteria from the tissue and communicating danger signals to other immune cells. To 
determine whether indole modulates the function of other antigen-presenting cells in 
addition to DCs, we tested several of our hallmark observations in bone marrow-derived 
and primary splenic macrophages. The completion of this abbreviated study has revealed 
these findings: 
 
1. Indole pre-conditioning suppresses pro-inflammatory cytokine production in 
macrophages. 
2. Pro-inflammatory signaling pathways are inhibited by indole conditioning in 
macrophages. 
3. The effects of indole on macrophages appear to be AhR-independent. 
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Rationale 
Macrophages are the most prevalent mononuclear phagocytes in the steady-state lamina 
propria and play a crucial role in tissue homeostasis (47). The ontogeny of intestinal 
macrophages is unique from other tissue-resident macrophages in that these cells display 
a short half-life, under constant renewal from circulating monocytes (143). We predict 
that these macrophage precursors encounter high concentrations of indole upon entering 
the intestinal environment, thus indole might play a role in shaping their inflammatory 
functions. Others have previously demonstrated that treatment of macrophages with the 
microbial metabolite, butyrate, can alter their function, primarily the down-regulation of 
pro-inflammatory mediators (70). Our findings in chapter two revealed that indole 
conditioning of DCs robustly dampened their subsequent responses to TLR-mediated 
inflammatory stimuli. Thus, our hypothesis is that treating macrophages with indole will 
result in a similar suppression of pro-inflammatory responses. 
 
Results 
Indole pre-conditioning suppresses pro-inflammatory cytokine production in 
macrophages 
We first investigated pro-inflammatory cytokine production in macrophages. Bone 
marrow-derived macrophages (BMDMs) were cultured to high purity (illustrated in 
Figure 3), routinely achieving >96% of cells bearing the hallmark macrophage signature 
of CD11b and F4/80 expressed on their surface. In our DC study, we typically 
conditioned DCs with indole during their development from bone marrow precursors in 
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order to mimic the proximity of DC progenitor cells to indole in the intestinal 
microenvironment during development. However based on the unique nature of 
intestinal macrophage ontogeny, we decided that a shorter treatment with indole would 
be more physiologically relevant as these cells are short-lived and continually being 
replenished from the circulation. We treated BMDMs for 18 hours with indole, followed 
by a 4 hour stimulation with either a very high (2 ug/ml) or low (250 ng/ml) dose of 
LPS. Intracellular cytokine staining revealed that production of both TNF and IL-12 
were inhibited by nearly 2-fold in macrophages treated with 1 mM indole (Figure 49). 
To see if recently arrived macrophage precursors might also be affected, we next treated 
BMDMs for just 4 hours with indole, followed by a 2 hour stimulation with the same 
LPS concentrations. Interestingly, we observed a similar inhibition of both cytokines 
even with this shorter duration of indole conditioning (Figure 49). Based on this 
observation, we conclude that even a short treatment with indole is sufficient to modify 
macrophage functions in response to inflammatory stimuli. 
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Figure 49. Treatment for 18 or 4 hours with indole inhibits TNF and IL-12 
production in BMDMs. 
 
BMDMs were treated with indole or DMF control for 18 hours or 4 hours, followed by 
stimulation with LPS (2 ug/ml or 250 ng/ml) for 4 hours in the presence of Golgiplug. 
BMDMs were then stained for intracellular TNF or IL-12 and analyzed by flow 
cytometry. (A) Red histograms represent unstimulated controls. Percentage of BMDMs 
producing cytokine are indicated on plots. (B) Aggregate data from 4 experiments with 
18 hours indole treatment for TNF production (left panel) or IL-12 production (right 
panel). * p < 0.05 by Student’s t test. 
  
A
B
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Macrophages and monocytes are the predominant source of harmful TNF production in 
inflammatory diseases (144), so we chose to test indole’s effects on primary 
macrophages ex vivo. Bulk splenocyte cultures were treated with indole overnight, then 
stimulated with LPS or heat-killed S. typhimurium to induce cytokine production. 
Splenic macrophages were distinguished by flow cytometric analysis as those cells 
negative for lineage markers and expressing very high levels of the integrin CD11b, a 
population that has been demonstrated to be macrophages derived from conventional 
hematopoiesis (145). Here, indole conditioning inhibited TNF production by primary 
macrophages by an astonishing 75% compared to solvent controls (Figure 50). When 
contemplating this result, it is important to consider that these were heterogeneous 
cultures, thus indole was also in contact with many other immune cells. As such, one 
explanation could be that indole affected other cells in the culture which then modified 
macrophage function indirectly. To rule out this possibility, future studies with purified 
primary macrophages would be required. However given the profound effects of indole 
on purified BMDMs, we theorize that the effect observed is due to indole’s direct action 
upon the splenic macrophages. 
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Figure 50. Indole conditioning inhibits TNF production in splenic macrophages ex 
vivo. 
 
Splenocytes were cultured for 24 hours with indole or DMF control, then stimulated 
with LPS (10 ug/ml) or HK-STM (4 x 107 CFU) for 6 hours in the presence of 
Golgiplug. Cultures were then stained for CD11b and CD11c and intracellular TNF and 
analyzed by flow cytometry. Analysis was confined to the distinct CD11bhi CD11cneg 
macrophage population. (A) Representative plots with percentage of TNF producing 
macrophages indicated. (B) Mean of three independent experiments. * p < 0.05 by 
Student’s t test. 
  
A B
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Pro-inflammatory signaling pathways are inhibited by indole conditioning in 
macrophages 
Based on our observation that cytokine production in macrophages is altered by a 
relatively short treatment with indole, we predicted that upstream pro-inflammatory 
signaling pathways are also affected. We focused our efforts on signaling pathways that 
we found to be inhibited by indole in DCs. The transcription factor, Stat3, is a central 
mediator of numerous physiological processes and has been suggested to be the 
predominant signal transducer downstream of gp130- like receptors (102). Contradictory 
findings have been reported for the role of Stat3 in APC signaling pathways, likely due 
to the pleiotropic nature of Stat3. Macrophage- specific ablation of Stat3 has been 
associated with dysregulation and heightened pro- inflammatory cytokine production in 
response to endotoxin (146); conversely, hyper- activation of Stat3 in a transgenic mouse 
model resulted in inflammation and macrophage-specific functional defects (147). These 
reports suggest that Stat3 activation is tightly regulated and that the macrophage lineage 
is sensitive to Stat3 activity. 
 
Stimulation of BMDMs with the canonical Stat3 activator, IL-6, following overnight 
indole conditioning revealed a robust inhibition of Stat3 phosphorylation. Treatment 
with indole reduced the number of macrophages undergoing Stat3 phosphorylation by 
50% and induced a similar inhibition of mean fluorescent intensity of the activated 
population (Figure 51). These data indicate that the Stat3 signaling pathway in 
macrophages is highly sensitive to indole. 
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BMDMs were treated with indole or DMF control for 18 hours, then stimulated with IL- 
6 (10 ng/ml) for the given times. Cells were stained for phospho-Stat3 and analyzed by 
flow cytometry. (A) Representative plots indicating percentage of pStat3-positive 
BMDMs. MFI values for pStat3+ population indicated in red. (B) Mean of three 
independent experiments. * p < 0.05 by Student’s t test. 
  
A
B 
Figure 51. Indole inhibits IL-6-induced pStat3 signaling in BMDMs. 
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The PI3K/Akt and MAPK/Erk signaling pathways regulate many cellular processes 
including survival, apoptosis, growth, and cytokine production. We have demonstrated 
in this study that Akt phosphorylation is inhibited by indole in DCs. Similarly, we found 
that indole conditioning dampened pAkt as well as pErk signaling in LPS and CpG- 
stimulated macrophages by approximately 50% (Figure 52). The inhibition of LPS- 
induced Akt activation has been demonstrated to decrease TNF production in 
macrophages (148). As such, indole’s upstream inhibition of Akt activation might 
provide a mechanism for the observed suppression of TNF production. Further 
investigation of this pathway would be required to test this hypothesis. Akt suppression 
has also been associated with decreased nitric oxide production in macrophages (148). In 
a future study, it would be useful to determine whether indole also produces this effect 
as NO is an important inflammatory mediator in macrophages. 
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Figure 52. Indole inhibits pAkt and pErk signaling in BMDMs. 
 
BMDMs were treated with indole (1 mM) or DMF control for 18 hours, then stimulated 
with LPS (10 ug/ml) or CpG (5 uM) for 30 minutes. Cells were stained for phospho-Akt 
(left panel) or phospho-Erk (right panel) and analyzed by flow cytometry. Percentage of 
positive-staining BMDMs indicated on plots. Representative data from one of three 
independent experiments. 
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It has been reported that specific inhibition of Erk in macrophages prior to LPS 
stimulation resulted in decreased NO production, while TNF and IL-12 expression were 
unaffected, indicating that Erk signaling is distinct from pro-inflammatory cytokine 
production (149). In support of this, butyrate conditioning of colonic lamina propria 
macrophages inhibited IL-6 and IL-12 expression, while MAP kinases including pErk 
were unaffected (70). In contrast, another group has reported short chain fatty acid- 
induced inhibition of Erk1/2 phosphorylation as well as decreased inflammatory 
mediators (iNOS, TNF, and IL-6) in the RAW264.7 macrophage line (150), suggesting 
potential crosstalk. These opposing findings demonstrate that MAP kinase signaling and 
pro-inflammatory cytokine production can be regulated independently. However, our 
observation that signaling pathways downstream of the LPS-detecting TLR4 are 
inhibited suggests that indole acts at the level of TLR signaling in its suppression of pro- 
inflammatory cytokine production. 
 
Excessive production of inflammatory mediators in macrophages is associated with 
numerous inflammatory diseases, including Crohn’s disease (151), metabolic disease 
(152), rheumatoid arthritis (153), and pulmonary fibrosis (154). Our preliminary 
observations suggest that indole is an effective small molecule inhibitor of multiple pro- 
inflammatory pathways and downstream cytokine responses. Future investigation of 
indole for anti-inflammatory therapeutic use might be useful in a number of clinically 
relevant diseases. 
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The effects of indole on macrophages appear to be AhR-independent 
In the current study, we have observed that indole’s effects in DCs are independent of 
the aryl hydrocarbon receptor, whereas concurrent work in our lab has revealed AhR 
dependence in indole’s effects on CD4+ T helper cells (Steinmeyer et al, in preparation). 
To address the question of indole and AhR dependence in macrophages, we acquired 
AhR-deficient mice and generated BMDMs from these animals. In repeating our earlier 
experiments using BMDMs derived from AhR-knockout mice alongside wild-type 
littermate controls, we found nearly identical effects of indole regardless of AhR status 
on the production of pro-inflammatory cytokines TNF and IL-12 (Figure 53). In both 
cases, cytokine production was reduced by approximately 2-fold subsequent to 
conditioning of BMDMs with 1 mM indole. 
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Figure 53. The indole-mediated inhibition of TNF production in BMDMs is AhR- 
independent. 
 
Flow cytometric analysis of BMDMs generated from WT or AhR-KO mice and treated 
with indole or DMF control for 18 hours. BMDMs were stimulated for 4 hours with LPS 
(50 ng/ml) in the presence of Golgiplug, then stained for intracellular TNF (left panels) 
and IL-12 (right panels). Gray histograms represent unstimulated samples and colored 
histograms are LPS-stimulated. Representative data from one of three independent 
experiments. 
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Similarly, we repeated our ex vivo indole conditioning of splenocytes with tissues from 
AhR-deficient and wild-type mice and analyzed TNF production. Overall TNF 
production was reduced by 25% or more in AhR-deficient macrophages compared to 
wild-type controls. However, a marked inhibition of cytokine production was observed 
with indole treatment in both groups, indicating AhR independence (Figure 54). 
Importantly, in this set of experiments we stimulated splenocytes with LPS, heat-killed 
S. typhimurium, and CpG. Indole pre-conditioning dampened TNF production in 
response to all three stimuli, indicating that the observed effects are not LPS-restricted 
but can be achieved through the activation of different TLRs. Further, our investigation 
revealed that indole’s robust inhibition of IL-6- mediated Stat3 phosphorylation in 
BMDMs was entirely AhR-independent (Figure 55). Conditioning with 1 mM indole 
reduced Stat3 signaling by over 60% regardless of AhR status, confirming that an 
alternative receptor is responsible for mediating indole’s effects in APCs. 
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Figure 54. The indole-mediated inhibition of TNF production in splenic 
macrophages is AhR-independent. 
 
Splenocytes from WT (left panel) or AhR-KO (right panel) mice were treated with 
indole or DMF control overnight, followed by stimulation for 6 hours with LPS (10 
ug/ml), HK-STM (4 x 107 CFU), or CpG (3 uM) in the presence of Golgiplug. Cells 
were surface stained for CD11b and CD11c followed by intracellular staining for TNF. 
Flow cytometric analysis was confined to the distinct CD11bhi CD11cneg macrophage 
population. Percentage of TNF-positive macrophages indicated on plots. Representative 
data from one of three independent experiments. 
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Figure 55. The indole-mediated inhibition of pStat3 signaling in BMDMs is AhR- 
independent. 
 
BMDMs were generated from WT (upper panel) or AhR-KO (lower panel) mice and 
treated with indole (1 mM) or DMF control for 18 hours. BMDMs were then stimulated 
with IL-6 (10 ng/ml) for the given times and stained for phospho-Stat3, which was 
detected by flow cytometry. Percentage of pStat3-positive BMDMs indicated on plots. 
Representative data from one of three independent experiments. 
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Discussion 
While the macrophage portion of our study is not to be considered comprehensive, we 
have successfully demonstrated that the microbiota metabolite, indole, induces profound 
alterations in macrophage signaling and pro-inflammatory cytokine production. These 
observations are important for multiple reasons. First, they reveal that indole’s effects 
are common to multiple antigen-presenting cell subsets and not restricted to DCs. This 
information helps to guide our search for the mechanism that mediates the effects of 
indole: based on similar observations in DCs and macrophages, a logical approach 
would be to focus on pursuing receptors that are present in both cell types. We could test 
receptor candidates using knock-out animal models or by incorporating receptor- 
blocking antibodies into our study to determine whether the effects of indole are reliant 
upon a particular cellular receptor. 
 
Second, they indicate that even a relatively short period of contact with indole is 
sufficient to induce physiological changes. This suggests that monocytes entering the 
intestines from circulation likely have the opportunity to be “instructed” by indole to 
dampen their inflammatory responses to TLR ligands, thus contributing to the 
tolerogenic landscape of the intestinal environment. This is important because compared 
to other tissue-resident macrophages, intestinal macrophages have a distinctly short half- 
life and are under constant renewal (116) and therefore sensitivity to local conditioning 
factors is likely a key factor in determining their function. As the most abundant 
mononuclear phagocytes in the lamina propria (155), macrophages play a key role in 
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promoting a tolerogenic environment and identifying a previously unknown endogenous 
signal that potentially drives this function would be novel. It has been demonstrated that 
during colitis, monocytes arriving in the intestines respond to pattern recognition 
receptor ligands by differentiating into pro-inflammatory macrophages that produce TNF 
and IL-12 among other inflammatory mediators (156). Because indole levels are low 
during colitis (93), we believe this supports our hypothesis that under steady-state 
conditions, high levels of indole in the intestines educate antigen-presenting cells to 
dampen pro-inflammatory responses to TLR stimuli. Under conditions of intestinal 
inflammation, however, indole levels are significantly depleted and macrophage 
precursors entering the gut are not exposed to this tolerogenic signal and instead further 
exacerbate inflammation as a result. 
 
Previously established gut-centric factors which specifically modify macrophage 
function are few. One such identified factor is intestinal epithelial cells, which produce 
tolerance-inducing molecules such as thymic stromal lymphopoeitin (TSLP), TGF-β, 
semaphorin 7A, and prostaglandin E2 to which intestinal macrophages are responsive 
(157). The reported HDAC-inhibitory activity of the SCFA, butyrate, was a seminal 
finding in the pursuit of microbiota components that confer tolerogenic properties upon 
intestinal macrophages (70). Here, the current study provides new information as to a 
novel microbiota signal which directly suppresses pro-inflammatory responses in 
macrophages. Both primary cultured and splenic macrophages were highly sensitive to 
indole upon a relatively short treatment period, supporting our hypothesis that indole is a 
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biologically relevant conditioning factor which suppresses inflammatory responses in 
macrophages upon arrival in the intestinal microenvironment. Further studies will be 
directed towards identifying the receptor for indole in APCs as well as investigating the 
effects of indole on macrophage-focused properties, such as bacterial clearance and 
epithelial wound healing. Based on our current and previous work that identifies indole 
as a beneficial signal in the gut, we hypothesize that indole will promote pathogen 
clearance and wound healing in intestinal macrophages. 
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CHAPTER V 
METHODS 
 
Mice 
C57BL/6 (WT), B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II), and B6.PL-Thy1a/CyJ (B6-
Thy1.1) mice were purchased from Jackson Laboratory (Bar Harbor, ME). C57BL/6- 
Ahrtm1.2Arte (AhR-KO) mice for initial experiments were a kind gift from Dr. 
Bhagavatula Moorthy (Baylor College of Medicine, Houston TX). Further AhR-KO 
mice were purchased from Taconic Farms (Rockville, MD). Mice were maintained in a 
specific pathogen-free animal facility located at Texas A&M University Health Science 
Center. All animal procedures were performed in accordance with the Institutional 
Animal Care and Use Committee guidelines under an approved animal use protocol. 
Mice were age and gender-matched for each experiment and used between 6 and 13 
weeks of age. 
 
Reagents 
Indole and all-trans retinoic acid were purchased from Sigma (St. Louis, MO). Indole 
was dissolved in dimethylformamide (DMF) and added to cultures at indicated 
concentrations. Recombinant murine GM-CSF and TGF-β1 were purchased from R&D 
Systems (Minneapolis, MN). Ultra-pure LPS from Invitrogen (San Diego, CA) was used 
for DC activation. Cell Rox Deep Red reagent for detection of reactive oxygen species 
(ROS) was obtained from Molecular Probes (Invitrogen, USA). Pacific Blue 
 136 
 
Succinimidyl Ester (PBSE) was used for discrimination of viable cells (Life 
Technologies). OVA323-339 peptide was purchased from AnaSpec, Inc. (Fremont, CA). 
Antibodies used for flow cytometry included CD4 (clone RM-5), CD11c (HL3), CD86 
(GL1), I-Ab (AF6-120.1), TNF (MP6-XT22), IL12 (c15.6), IL-6 (MP5-20F3), phospho- 
Stat3 (4/P-STAT3) and LPAM-1/α4β7 (DATK32) purchased from BD Biosciences (San 
Jose, CA). Anti-Foxp3 (FJK-16s), CCR9 (CW-1.2), CD45R/B220 (RA3-6B2) and 
TLR4/MD-2 (MTS510) were purchased from eBioscience (San Diego, CA) and 
phospho-Akt (193H12) and phospho-NF-kB p65 (93H1) were purchased from Cell 
Signaling Technology (Beverly, MA). 
 
Cell culture 
DC culture and stimulation 
The murine dendritic cell line DC2.4 was kindly provided by Dr. Kenneth Rock, 
University of Massachusetts Medical Center. DC2.4 cells were maintained in complete 
DMEM medium (Invitrogen, Grand Island, NY) supplemented with 5% fetal calf serum 
(FCS). All primary cells were cultured in RPMI 1640 supplemented with 2- 
mercaptoethanol, gentamicin, penicillin, streptomycin, and 10% FCS (all from Life 
Technologies). Bone marrow-derived dendritic cells were cultured as previously 
described (94) with slight modifications. Briefly, bone marrow cells were harvested from 
murine femurs and cultured in complete media supplemented with 10% FCS, 20ng/ml 
GM-CSF (Peprotech), and 10ng/ml IL-4 (Peprotech). Media was replenished at day 2, 4, 
and 6 of the 7 day culture. Indole, RA, or solvent control were added to the cultures at 
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day 3 where indicated. Stimulation of dendritic cells at the given concentrations of LPS 
or heat-killed S. typhimurium were performed for 4 hours (DC2.4 and BMDCs) or 6 
hours (primary splenic DCs) in the presence of Golgi-Plug protein transport inhibitor 
(BD Biosciences) to measure cytokine production, or for 24 hours (co-stimulatory 
markers). 
 
Macrophage culture 
Bone marrow was harvested as described above and cultured at a density of 1 x 106 cells 
in 10 ml complete media supplemented with 10 ng/ml M-CSF (Peprotech) in 100mm x 
15mm petri dishes. Media with cytokine was replenished on day 3. Adherent and semi- 
adherent cells were recovered on day 7, plated, and treated with indole prior to 
downstream experiments. 
 
Assays 
NF-kB activity assay 
The DC2.4-NFkB-GLuc cell line was generated by our collaborators (Arul Jayaraman 
Lab, Chemical Engineering Dept, TAMU). A reporter plasmid with tandem repeats of 
NF-kB response element was designed and integrated into the genomic DNA of the 
DC2.4 cell line via lentiviral transduction. A minimal inducible cytomegalovirus (CMV) 
promoter was cloned upstream of GLuc (Gaussia luciferase, a secreted reporter) to 
monitor NF-kB activation. The inducible promotor is inactive in the absence of NF-kB 
binding to DNA. DC2.4-NFkB-GLuc cells were pre-treated with indole and/or TGF-β 
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for 24 hours followed by LPS stimulation (10 ug/ml). Culture supernatants were 
collected at 8 and 24 hours and assayed for GLuc using Biolux Gaussia Luciferase assay 
kit (New England BioLabs). 
 
Cytotoxicity assay 
The CytoTox96 non-radioactive cytotoxicity assay (Promega) was used to identify 
cytotoxic effects of indole. Cells were treated with or without indole for various 
durations and the amount of lactate dehydrogenase (LDH) released into the culture 
supernatant was measured. 
 
Reactive oxygen species (ROS) production 
Reactive oxygen species production was measured using the CellRox Deep Red Reagent 
(ThermoFisher). Briefly, cells were treated with or without indole for 18 hours, then 
labeled with CellRox (5 uM) for 30 minutes and washed with PBS followed by LPS 
stimulation. Presence of ROS oxidizes the CellRox reagent to a fluorescent state that can 
be subsequently analyzed via flow cytometry. 
 
Nitric oxide (NO) production 
Nitric oxide concentration was determined by measuring nitrite levels in culture 
supernatants via the Griess reaction (178). Briefly, cells in the presence or absence of 
indole were stimulated with LPS for 24 hours. Supernatants were then incubated with 
Griess reagent for 10 minutes and then absorbance was measured at 550nm. 
 139 
 
Antigen-uptake assay 
Ovalbumin (OVA)- Alexafluor 488 conjugate (Molecular Probes) was used for 
measuring antigen uptake by DCs. Subsequent to 24 hour indole conditioning, cells were 
incubated with 1µg/ml OVA-A488 at 4°C or 37°C for 1 or 4 hours. Cells were then 
washed 3 times with ice-cold PBS containing 0.5% BSA to terminate uptake. Cells were 
surface stained for CD11c and fixed with 4% paraformaldehyde. Uptake of OVA-A488 
was measured by flow cytometry. 
 
Aldehyde dehydrogenase activity 
Activity of aldehyde dehydrogenase (ALDH) in individual BMDCs was measured using 
an Aldefluor staining kit (Stem Cell Technologies) according to the manufacturer’s 
instructions with minor modifications. Briefly, BMDCs were incubated with Aldefluor 
substrate (150 nm) for 45 minutes at 37°C, with or without ALDH inhibitor 4- 
(diethylamino) benzaldehyde (DEAB) at (100 µm). Subsequently, cells were stained 
with CD11c in cold Aldefluor assay buffer and then analyzed by flow cytometry. 
 
Real-time PCR 
Total RNA was extracted from BMDCs using RNeasy Mini Kit (Qiagen) and then retro- 
transcribed using cDNA Superscript Mastermix (Quanta). Quantitative PCR reactions 
were carried out in triplicate using Perfecta SYBR Green Fast Mix, Low ROX (Quanta).  
Gene expression levels for each individual sample were normalized to 18s. Mean 
relative gene expression was determined and differences were calculated using the  
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2-∆C(t) method. The following primer sequences (5’-3’) were used: 
Murine aldh1a2 
F: CATGGTATCCTCCGCAATG R: GCGCATTTAAGGCATTGTAAC 
Murine 18s 
F: TCAACTTTCGATGGTAGTCGCCGT R: TCCTTGGATGTGGTAGCCGTTTCT  
 
ELISA 
Cytokine concentration in the supernatant of BMDC cultures was assessed using 
commercially available ELISA kits for IL-10 (Peprotech) and TGF-β (eBioscience) per 
the manufacturer’s instructions. 
 
Chemotaxis assay 
24-well Transwell cell culture plates with 8.0 uM polycarbonate membranes were used 
for this assay (Corning) along with chemokines CCL25 (CCR9 ligand), CCL19 and 
CCL21 (CCR7 ligands; all from Peprotech). A volume of 600 ul cell culture media 
containing 1 ug/ml of either CCL25 or CCL19 and CCL21 was placed in the bottom 
chamber, followed by the transwell insert. BMDCs conditioned with indole, RA, or 
DMF from day 3 were harvested and washed on day 7. Exactly 100 ul of cell culture 
media containing 4.5 x 105 BMDCs was added to the upper chamber of the transwell.  
Controls without the presence of chemoattractants were included. Plates were incubated 
for 3 hours at 37°C, at which point transwell inserts were removed and migrated cells in 
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the bottom chamber were collected and counted. Migration is expressed as a percentage 
of the initial cell number.  
 
DC-T cell co-cultures (polyclonal stimulation) 
Naïve CD4+CD25- T cells from pooled spleen and lymph nodes of C57BL/6 wild-type 
mice were sorted to high purity (>97%) on a BD FACS Aria II flow cytometer (BD 
Biosciences). Antibodies used for staining were αCD4 (GK1.5) and αCD25 (PC61.5). 
BMDCs were previously treated with indole from day 3. On day 7, DCs were washed 
extensively prior to being co-cultured with the naïve FACS-sorted T cells for 72 hours in 
a 96-well round-bottom tissue culture plate in the presence of soluble anti-CD3 at 
5ug/ml (BioXcell clone 145-2C11) as well as 2 ng/ml TGF-β (Peprotech) and/or 100 
U/ml IL-2 (Roche). Subsequently, cells were stained for flow cytometric analysis using 
αCD4 (GK1.5) and αFOXP3 (FJK-16s). 
 
DC-T cell co-cultures (monoclonal stimulation) 
Naïve CD4+CD25- T cells of spleen and lymph nodes from OT-II mice were isolated by 
negative selection via column purification using the Naïve CD4+ T Cell Isolation Kit 
(Miltenyi Biotec). Naïve CD4+ T cells (>96% pure) were labeled with Cell Proliferation 
Dye efluor450 (eBioscience) following manufacturer’s instructions then co-cultured 
with OVA peptide-loaded BMDCs at a ratio of 2:1 for 72 hours in a 96-well round- 
bottom tissue culture plate. BMDCs were previously treated with indole or RA from day 
3. On day 7, DCs were washed extensively prior to being loaded with OVA323-339 peptide 
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(10ug/ml) for 1 hour at 37°C. BMDCs were then washed three times and plated with 
naïve CD4+ T cells. RA or TGFβ were added to co-cultures as indicated. Following 3 
days of culture, cells were stained with antibodies to CD4, CCR9, and LPAM-1 (α4β7). 
Intracellular staining for Foxp3 was performed using a Foxp3 staining kit (eBioscience). 
The remaining CD4+ helper T cell lineages Th1, Th2, and Th17 were identified by their 
cytokine production. For Th2 and Th17 differentiation cultures, lineage skewing 
cytokines were included for the duration of the co-culture. For Th2 skew, cultures 
received 0, 10, 50, or 100 ug/ml of each αIFN-γ (BioXCell R4-6A2) and IL-4 
(Peprotech). For Th17 skew, cultures received 0, 10, or 50 ng/ml each of TGF-β 
(Peprotech), IL-6 (Peprotech), and IL-23 (R&D). Production of cytokines was stimulated 
by the addition of PMA and ionomycin (Sigma-Aldrich) during the last five hours of 
culture. Cytokines were retained inside the cells by the addition of the protein transport 
inhibitor, Golgiplug (BD) at the time of stimulation. Cells were fixed and permeabilized 
using the Foxp3 staining kit (eBioscience). Antibodies used for intracellular cytokines 
were αIFN-γ-PE (eBioscience XMG1.2), αIL-4-FITC (eBioscience BVD6-24G2), and 
αIL-17-efluor660 (eBioscience eBio17B7) to detect Th1, Th2, and Th17 cells, 
respectively. 
 
DC-T cell co-cultures without cell contact 
Naïve CD4+CD25- T cells were FACS-sorted and placed in the bottom of a 24-well 
Transwell cell culture plate with 0.4 uM polycarbonate membranes (Corning) that had 
been coated with 5 μg/mL αCD3 (BioXcell 145-2C11) and 2 μg/mL αCD28 (BioXcell 
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37.51). TGF-β was added at the indicated concentrations. The insert was placed in the 
well and washed, Day 3-treated BMDCs were added to the top chamber such that culture 
media was shared, but the cell types were kept physically separate. The T cell to DC 
ratio was 2:1, as in other co-culture experiments. 
 
T cell activation in the presence of BMDC supernatant 
Naïve CD4+CD25- T cells were FACS-sorted as described above and plated in 96-well, 
αCD3 and αCD28-coated tissue culture plates in a volume of 100 ul cell culture media. 
An equal volume of spent BMDC supernatant was added, in the presence or absence of 
exogenous TGF-β, and T cells were cultured for 72 hours. To generate supernatants, day 
3-treated BMDCs were collected on day 7, washed extensively and plated in a 48-well 
cell culture plate at 5 x 105 cells per well in 500ul fresh complete media for 24 hours in 
the presence or absence of 1 ug/ml LPS. Plates were then centrifuged and supernatants 
were collected, filtered, and stored at -20°C until use. 
 
In vivo T cell activation by indole-treated BMDCs 
Naïve CD4+CD25- T cells from spleens and lymph nodes of OT-II mice were isolated 
by column purification as described above and resuspended in sterile Hanks Balanced 
Saline Solution (HBSS). Approximately 2 million T cells were transferred via i.v. 
injection (retro-orbital route) into recipient B6-Thy1.1 mice. Day 7 BMDCs cultured 
with indole, RA, or DMF from day 3 were washed and loaded with OVA peptide as 
described above. Two million BMDCs were resuspended in sterile HBSS and transferred 
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i.p. into the same B6-Thy1.1 recipient mice 5 hours subsequent to T cell transfer. After 5 
days, tissues were harvested for cellularity analysis as well as ex vivo stimulation for 
cytokine production. 
 
BMDC transfer with DSS-colitis 
BMDCs were cultured with indole, RA, or DMF from day 3 as described above. 
BMDCs were washed, counted, and resuspended in sterile PBS (Ca-Mg-) for transfer to 
WT C57BL/6 recipients. Two million BMDCs were transferred via i.p. injection on days 
0, 6, and 9 of the experiment. Mice received 5% dextran sulfate sodium (DSS, MW= 
36,000-50,000; MP Biomedicals) ad libitum in their drinking water from day 7 through 
day 14. Mice were weighed daily to monitor weight loss. Mice were euthanized on day 
20 for subsequent tissue harvest and processing. 
 
Statistical analysis 
Data were analyzed using GraphPad Prism Software 5.01. Comparisons between DMF 
and indole were performed using a Student’s t test. One-way ANOVA followed by 
Dunnett’s post test was applied to compare differences in experiments with DMF, 
indole, and RA treatment groups. P values of less than 0.05 were considered to be 
statistically significant. 
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Subsets of dendritic cells in the GALT can produce retinoic acid from vitamin A and 
subsequently regulate immunity via mechanisms including imprinting lymphocytes with 
gut-homing specificity and driving Foxp3+ regulatory T cell development. Indeed, 
retinoic acid has been previously identified as an essential co-factor in the induction of 
Foxp3+ Tregs by bona-fide, CD103+ mucosal dendritic cells (55). Our overall findings 
reveal that a novel microbiota-derived metabolite, indole, conditions DCs towards a 
mucosal phenotype in a manner unique from retinoic acid and these indole-conditioned 
DCs are capable of promoting a regulatory phenotype in naïve T cells (Figure 56). 
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Figure 56. Indole conditioning promotes a tolerogenic phenotype and function in 
DCs. 
 
The current study identifies numerous effects of indole conditioning on DCs as indicated 
in diagram. These properties are consistent with properties of bona fide mucosal DCs 
present in the intestinal environment. 
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The molecular mechanism for indole’s effects on APCs remains unknown 
While our study has revealed striking and previously unappreciated biology, the 
molecular mechanism of action by which indole affects APCs remains to be 
characterized. Despite our identification of indole as a ligand of the aryl hydrocarbon 
receptor (83), our work using AhR-deficient animals has revealed that indole’s effects on 
APCs are entirely AhR-independent. The small size and freely diffusible nature of indole 
might suggest an intracellular receptor in APCs. In addition, indole seems to affect APCs 
in a manner similar to TGF-β and retinoic acid, both of which bind intracellular 
receptors. Further, indole’s effects on APCs occur fairly rapidly, as we observed defects 
in phospho-signaling with as little as four hours indole pre-conditioning (data not 
shown). 
 
Our observation that soluble factors do not appear responsible for indole-DC mediated 
Treg skew was surprising, as the comparable canonical factors RA and TGF-β are both 
soluble factors. However, the results of our study suggest that cell contact between the 
DC and naïve T cell is required for T cell lineage skewing and has thus directed our 
search for mechanism towards targets on the cellular surface. We have identified the 
programmed death (PD) 1-PD-ligand (PD-L) pathway as a possible candidate. PD-1 is 
an inhibitory receptor of the CD28/CTLA4 family expressed on activated lymphocytes 
and with a role in regulating tolerance and autoimmunity. Its ligands, B7-family 
members PD-L1 (B7H1) and PD-L2 (B7-DC), are expressed broadly on hematopoietic 
cells and restricted to DCs and macrophages, respectively (158, 159). It has been 
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demonstrated that PDL-1 can promote and support Tregs by inducing and enhancing 
Foxp3 expression in peripherally activated T cells (160). Further, this effect is mediated 
through the inhibition of Akt/mTOR signaling (160), an effect we have observed here in 
indole-treated APCs. Thus, indole-induced upregulation of PD-1 ligands on DCs might 
be a cellular mechanism by which indole-conditioned DCs promote Tregs, and we plan 
to test this hypothesis in subsequent mechanistic studies. 
 
An intriguing finding in this study was that indole’s direct effects on DC phenotype and 
function occurred in the absence of any exogenous co-factors, whereas indole- 
conditioned DCs required TGF-β or retinoic acid to affect naïve T cell activation. This 
might suggest that more than one receptor or pathway mediates indole’s effects on 
APCs. Determining the mechanism(s) of action of indole on DCs is a crucial next step in 
this study. A transcriptomics approach would be useful to identify rational targets and 
signaling pathways that mediate the observed effects. 
 
AKT/mTOR pathway as a potential target of indole in APCs 
One pathway that we predict might mediate indole’s effects on APCs is mammalian 
target of rapamycin (mTOR)/autophagy signaling. First described in 1991, TOR was 
identified as a target of the bacteria-derived immunosuppressant, rapamycin (161). 
mTOR is an evolutionarily conserved protein kinase that plays a central role in balancing 
cell growth and the lysosomal degradation process known as autophagy. As such, mTOR 
allows cells to adjust their metabolism based on environmental signals including nutrient 
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starvation and stress. Under low nutrient conditions, mTOR induces autophagy, which 
degrades intracellular components including damaged or non-essential organelles, 
misfolded proteins, and intracellular pathogens, thus providing additional energy sources 
to promote cell survival. 
 
As demonstrated in chapter two, we have found that indole strongly inhibits Akt 
signaling in DCs. Hyperactivation of Akt is a hallmark of many solid tumors (162) and 
has been linked to tumor aggressiveness (163). While model systems have shown these 
tumors to be highly sensitive to mTOR inhibitors, use of the inhibitors in human cancer 
patients has shown minimal success due to the release of an inhibitory mechanism 
ultimately resulting in upregulated Akt and mTOR (164). It has therefore been suggested 
that small molecule mTOR inhibitors that prevent Akt activation might be highly useful 
as anticancer therapies. Based on our preliminary data, we would recommend that indole 
and related metabolites be investigated for development as potential therapeutics against 
tumors. 
 
Our preliminary experiments suggest that, like rapamycin, indole induces autophagy in 
DCs (data not shown). The importance of autophagy in DCs has been well documented. 
For example the bacterial sensor, NOD2, has been shown to induce autophagy in DCs, 
an effect that was necessary for bacterial clearance as well as MHC-II-mediated antigen- 
specific CD4+ T cell responses in DCs (165). Thus, we predict that indole may provide a 
beneficial effect on host cell survival and intracellular bacterial clearance by regulating 
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the mTOR/autophagy pathway. Futures studies exploring effects of indole at multiple 
checkpoints along this pathway will be useful for clarification. 
 
We have observed similar effects of indole and rapamycin on the inhibition of 
downstream mTOR target, phospho-S6 in naïve T cells (Figure 57), suggesting that both 
inhibit mTOR activity. This might indicate that indole acts as a “rapalog”, mimicking 
rapamycin activity. However, we have found differential effects on DC cytokine 
production: indole inhibits pro-inflammatory IL-12 and does not affect anti- 
inflammatory IL-10, whereas rapamycin stimulates IL-12 production and inhibits IL-10 
under similar LPS stimulation conditions (166). Thus, despite some apparent 
overlapping biological effects, indole cannot be characterized as a rapalog in DCs. It is 
interesting to note that while both bacteria-derived compounds, indole is a naturally- 
occurring microbiota metabolite present in the human GI tract whereas rapamycin is 
produced by the soil-dwelling bacterium, Streptomyces hygroscopicus (167) and thus 
bears no direct relevance to human physiology. Subsequent research efforts in our lab 
will be devoted to exploring this pathway as a potential target of indole in immune cells. 
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Figure 57. Indole inhibits phospho-S6 in purified CD4+CD25- T cells in an AhR- 
independent manner. 
 
Wild type (upper panel) or AhR-KO (lower panel) CD4+CD25- T cells were sorted to 
high purity and cultured with indicated treatments for 18 hours. Treatment 
concentrations were indole at 1, 0.5, and 0.25 mM, Rapamycin at 25 nM, and AICAR at 
0.5 mM. Phospho-staining was then performed for the S6 ribosomal protein and 
analyzed by flow cytometry. Percentage of pS6-positive cells indicated on plots. 
Representative data from one of two experiments. 
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Expand study to include macrophage-specific and B cell biology 
This work largely focused on dendritic cells, as these antigen-presenting cells act as the 
predominant activators of naïve T cells in vivo and thus have a crucial role in bridging 
innate and adaptive immunity. However, macrophages are not only capable of activating 
naïve T cells, but they play an important role in preventing aberrant mucosal 
inflammation. Our abbreviated study indicated that indole affects macrophages in a very 
similar manner to DCs, and these effects appear AhR-independent in both immune cell 
subsets. Further work with indole focused on biology pertinent to macrophage functions, 
such as bacterial clearance and wound healing, would be enlightening. 
 
While antigen presentation is not their primary role, B lymphocytes represent the 
remaining subset of professional antigen-presenting cells in addition to DCs and 
macrophages. B cells can engulf protein antigens and present the peptide: MHC-II 
complex to CD4+ T cells within lymphoid organs. The engaged helper T cell responds to 
this interaction by upregulating CD40 ligand and secreting cytokines, both signals that 
reciprocally activate the antigen-presenting B cell. The B cell will then proliferate and 
differentiate to an antibody-secreting plasma cell. In mucosal tissues, IgA is the 
dominant class of antibody and is produced locally by plasma cells in the mucosal wall 
(168). Secreted IgA binds the mucus layer covering the intestinal epithelium and serves 
a crucial protective role in the intestinal microenvironment by limiting the access of 
pathogens to mucosal surfaces, a phenomenon termed immune exclusion (169). In 
addition, IgA possesses minimal capacity to activate the classical complement pathway 
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or to act as an opsonin, therefore IgA does not induce inflammation and contributes to 
mucosal tolerance (170). Naïve B cell precursors of IgA-secreting plasma cells become 
activated in gut-associated lymphoid tissues, thus we predict direct contact of these 
precursor cells with indole or indole-conditioned DCs. We have demonstrated that 
primary splenic B cells are sensitive to treatment with indole, exhibiting similar 
inhibition in signaling as observed in DCs. We have found that 1 mM indole suppresses 
pAkt and pErk signaling by 50% or more in splenic B cells in an AhR-independent 
manner (Figure 58). Based on our observations thus far that indole promotes tolerance in 
several immune cell types, we hypothesize that indole may additionally contribute to 
immune homeostasis by stimulating B cell class-switching to IgA-producing plasma 
cells. 
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Figure 58. Indole inhibits pAkt and pErk signaling in splenic B cells in an AhR- 
independent manner. 
 
Splenocytes from wild type (upper panel) or AhR-KO (lower panel) mice were cultured 
for 18 hours with indole or DMF control, followed by stimulation with CpG (3 uM) and 
phospho-staining for phospho-Akt (left) and phospho-Erk (right). Flow cytometric 
analysis was confined to B220+ B cells. Percentage of positive-staining B cells indicated 
on plots. Representative data from one of two experiments. 
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Continue pursuing in vivo protection in colitis models 
In this study we have utilized the DSS murine model of colitis to test for in vivo 
protective effects of indole-conditioned DCs. While we did not observe protection, we 
believe that a number of factors might account for this result, including the number of 
DCs transferred and its timing, as well as severity of the inflammatory insult and a 
potential requirement for IL-6 as a reparative factor (137). In addition, route of indole 
administration is an important factor to consider as different routes likely have differing 
bioavailabilities and final concentrations in tissues. We have plans to continue pursuing 
this model with a modified approach, utilizing multiple cycles of low-dose DSS in order 
to more accurately represent the chronic colonic inflammation associated with 
inflammatory bowel disease in humans. Our prediction is that longer term conditioning 
of the mucosal tissues with adoptively transferred indole-DCs will reveal a protective 
effect by dampening the inflammatory signaling associated with DSS-colitis. 
 
Murine models of intestinal inflammation are typically categorized as being induced by 
chemicals, gene knockout, or CD4+ T cell reconstitution of immune-deficient mice. A 
careful consideration of the available models and their mode of action is necessary to 
choose the most appropriate system. We chose the chemically induced DSS model due 
to its widespread use, reproducibility, and mechanism of intestinal injury. Oral delivery 
of DSS results in pathology analogous to human ulcerative colitis, as evidenced by 
epithelial layer damage and permeability, acute inflammation, and infiltration of 
neutrophils and macrophages (171). The other widely used chemically induced model is 
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administration of the haptenating agent, TNBS. This compound is administered intra- 
rectally and elicits a severe inflammatory response followed by tissue necrosis, 
resembling human Crohn’s disease (172). Successful protection against colitis has been 
recently achieved in this model when DCs were treated with a microbiota component, 
then adoptively transferred to recipient mice prior to TNBS administration (73, 127). 
Based on this observation, it is possible that DCs play a more predominant role in the 
TNBS colitis model and as such, it may be worth considering the application of this 
model to our indole-conditioned DC system. 
 
Examine potential benefit of indole in sepsis model 
An alternative health condition that might benefit from indole-conditioned DC transfer 
would be sepsis. Each year over a million Americans suffer from septic shock, a life- 
threatening inflammatory response to overwhelming infection. The Agency for 
Healthcare Research and Quality lists sepsis as the most expensive condition treated in 
U.S. hospitals, costing more than $20 billion in 2011 and increasing on average annually 
by 11.9 percent (173). Despite decades of clinical trials targeting the treatment of sepsis, 
no significant therapeutic success has been achieved and the number of sepsis cases per 
year continues to rise. Novel treatment strategies are desperately needed. 
Lipopolysaccharide is a component of the cell wall of bacteria and known to be one of 
the primary inducers of septic shock. Sepsis is characterized by massive pro- 
inflammatory cytokine release and excessive recruitment of immune cells, which can 
lead to multiple organ failure, dangerously low blood pressure, and ultimately, death. 
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A review of the literature reveals the LPS sepsis model as a well-characterized, relevant 
and practical means of studying septic shock-induced death. Injecting rodents with LPS 
is the most extensively studied animal model of sepsis, utilized for over 40 years (174). 
This endotoxin model is consistent, reproducible, and easily standardized. Upon 
injection of LPS, a systemic inflammatory response is initiated that resembles the 
systemic inflammatory response in human patients with severe sepsis, characterized by 
increased circulating concentrations of numerous cytokines (175-177). 
 
We have demonstrated that indole conditioning drastically dampens pro-inflammatory 
cytokine production by APCs upon LPS stimulation. Based on these observations, we 
propose that pre-treatment with indole will condition host cells to be less responsive to 
subsequent inflammatory insult, thus preventing death from septic shock. If successful, 
the further development of indole and other metabolites for therapeutic use in the context 
of preventing sepsis would be highly advantageous in a clinical setting and has the 
potential to save thousands of lives. 
 
Additional microbiota metabolites as immune modulators 
It is important to consider that this work examined the effects of a single microbiota 
metabolite. In the true physiological environment, immune cells are undoubtedly in 
contact with a multitude of various metabolites at any given time. Thus, parameters such 
as developmental stage of the immune cell, metabolite concentration, and duration of 
exposure are likely to play a role in metabolite conditioning of immune cells. 
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Determining the cellular receptors to which particular metabolites bind will be useful in 
further understanding host-microbiota crosstalk. We have recently demonstrated that 
metabolite structure is extremely important in these interactions: indole and 5-hydroxy- 
indole, which differ by a single hydroxyl group, exhibit reciprocal effects on Treg and 
Th17 differentiation (Steinmeyer et al, in preparation). As such, it is likely that diverse 
metabolite classes exist that impose differential effects on immune cells in the gut. 
Future studies will be useful to investigate the effects of multiple, physiologically 
relevant metabolites in concert in order to better mimic the in vivo environment. 
 
Closing remarks 
Antigen-presenting cells in the gut provide a crucial function for the host, driving 
peripheral tolerance towards innocuous antigens and preventing aberrant inflammation. 
While host-derived factors are known to drive these properties in mucosal APCs, few 
specific microbiota signals have been identified that modulate mucosal APC 
characteristics. Previous work from our lab and others has demonstrated a protective role 
of the endogenous microbiota metabolite, indole, in the GI tract. The experiments 
described in this thesis uncover a previously unappreciated role for indole in instructing 
dendritic cells towards a mucosal phenotype and function, thus providing evidence for a 
single metabolite promoting peripheral tolerance (see Figure 59 for schematic 
 representation). This revelation paves the way for future work in manipulating the 
microbiota for therapeutic potential in autoimmune and inflammatory disorders of the GI 
tract. 
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Figure 59. Indole is a microbiota signal that confers mucosal properties upon 
intestinal APCs. 
 
Known gut-centric molecules which induce tolerogenic APCs include microbiota- 
derived short-chain fatty acids (SCFA) and Bacteroides fragilis with its outer membrane 
component, polysaccharide A (B. fragilis- PSA). The established, predominant host- 
derived factors which drive tolerogenic DC properties are the cytokine transforming 
growth factor-β (TGF-β) and the dietary vitamin A metabolite, retinoic acid (RA). 
Mucosal DCs express high levels of the enzyme aldehyde dehydrogenase 1a2 (aldh1a2) 
which catalyzes the RA-producing reaction, thus producing high concentrations of RA in 
the microenvironment. This RA acts directly upon DCs and CD4+ T cells to affect gene 
transcription for downstream effects including preferential induction of Foxp3+ Tregs, 
expression of gut-homing CCR9 receptors, class switching to IgA+ in B cells, and 
suppressed inflammatory responses to TLR stimuli. The tryptophan metabolite, indole, is 
an additional intestinal signal which induces mucosal properties in DCs in a manner 
independent of RA metabolism. Indole also inhibits pro-inflammatory responses to TLR 
stimuli in macrophages, promoting a tolerogenic environment. 
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